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Abstract 
Rett syndrome (RTT) is a progressive neurological disorder affecting 1 in 10.000 
live female births; nowadays is the most common genetic cause of intellectual 
disability in females. RTT is characterized by a normal pregnancy period and an 
apparently normal early post-natal phase. Around 6-18 months of life children lose 
all the previously acquired skills and manifest overt symptoms (as autistic features, 
loss of purposeful hand use, respiratory abnormalities and motor dysfunctions). 
Classical RTT cases are linked to mutations in the X-linked MECP2 gene that 
encodes for the Methyl-CpG-Binding Protein 2 (MeCP2), a multi-functional protein 
ubiquitously expressed in the body.   
The apparently normal early post-natal period explains why most of the studies in the 
RTT field focused post-natally, while the role of the protein during early 
development was only partially investigated. However, nowadays, many evidences 
demonstrating the presence of earlier symptoms in both girls and RTT animal models 
are arising. Therefore, we decided to investigate the role of Mecp2 during 
early/embryonic cortical development, as the cerebral cortex morphology is altered 
in RTT and patients manifest cognitive impairments. We demonstrated that E15.5 
cortices are characterized by an altered expression profile suggestive of a delay in 
neuronal maturation. Thus, we analysed neuroprogenitors highlighting that Mecp2 
absence slightly alters the cell cycle progression, lengthening the permanence of cells 
in the G1 phase. This possibly impairs the proper definition of cell fate, as Mecp2 
null embryonic cortices are characterized by the increment of cells transitioning from 
progenitors to post-mitotic neurons. Interestingly, the altered switch is in line with 
the maturation delay suggested by our transcriptional analysis, as the impaired fate 
definition can delay the expression of genes characterizing more mature cells as 
different glutamate receptors and ion channels subunits. Cells, delayed in their 
maturation since early/embryonic phases, are not properly responding to external 
stimuli, resulting in their defective integration in the forming network, which is a 
feature common to many autistic spectrum disorders. Our data represent a first 
evidence of the importance of Mecp2 during embryonic development and suggest 
that the phenotype characterizing RTT patients is due to the sum of different 
alterations occurring since embryonic development and worsening through life. 
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1. INTRODUCTION 
 
1.1 Rett syndrome 
 
It was 1966 when Dr. Andreas Rett published a first description of a syndrome 
characterizing different young females all in paediatric ages and showing common 
features and unusual behaviours. Unfortunately, the pathology remained unknown 
for at least other 20 years, probably due to its rarity and to the fact that Dr. Rett 
published exclusively in the German medical literature. The description of a larger 
group of girls affected by Rett syndrome (named in honour of Dr. Rett; RTT; OMIM 
#312750) was published in English almost twenty years later, bringing the pathology 
to be internationally recognized (Chahrour and Zoghbi, 2007; Lombardi et al., 2015). 
RTT is a progressive neurological disorder affecting 1 in 10.000 live female births.  
 
 
Figure 1.1 Onset and progression of clinical symptoms of RTT. Patients affected by RTT go through a 
common progression of symptoms. They usually are normal at birth, but then enter in a phase of developmental 
stagnation, followed by a rapid regression with the manifestation of autistic features, a stationary phase and 
finally a late motor deterioration (Chahrour and Zoghbi, 2007). 
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Nowadays RTT is the most common genetic cause of severe intellectual disability in 
females (Gadalla et al., 2011); its severity and clinical presentation can be widely 
variable but a cascade of symptoms common to most of the patients can be 
recognized (Fig 1.1). 
RTT is characterized by a normal pregnancy period followed by an early post-natal 
phase without symptoms; importantly, considering this phase as completely 
symptoms-free is incorrect, as many retrospective analysis showed that hypotonia is 
already present in the “pre-symptomatic” phase and development in general present 
subtle, but consistent, alterations (Smeets et al., 2012). Between 6 and 18 months of 
age, a phase of developmental stagnation is usually recognizable. This stage is 
characterized by (i) the inability to acquire different developmental milestones (as 
word development, social interaction and motor functions), (ii) the delay of growth, 
(iii) the appearance of microcephaly and (iv) strong muscle hypotonia, generating the 
so-called “weak posture”. Afterwards, the pathology rapidly develops with the 
deterioration period, in which any previously acquired milestone is lost and other 
symptoms appear. If children were walking or standing, speaking or babbling they 
generally lose these capabilities; moreover they start showing strong autistic features 
as social withdrawal, irritability, self-abusive behaviour and indifference to the 
surrounding environment together with one of the classical features of RTT, the lost 
of purposeful hand use that is replaced by stereotypical movements (usually clasping 
or hand washing movements). Often, in this phase, patients develop respiratory 
abnormalities (as hyperventilation or apneas) and motor dysfunctions (as apraxia or 
ataxic gait). The deterioration period is followed by a pseudo-stationary phase, that 
starts between 3 and 10 years of age, in which usually social interaction and autistic 
features ameliorate, as children appear more alert and joyful. The improvement is 
only partial, in fact children in this stage generally develop seizures and scoliosis. 
The last phase is the so-called late motor deterioration; patients often become 
wheelchair dependent, presenting muscle waste and circulation problems. At this 
stage the neurological impairment become even severer and patients may develop 
Parkinsonian features (Chahrour and Zoghbi, 2007; Lombardi et al., 2015). 
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1.2 The genetic of RTT 
 
Since the first descriptions of RTT it was evident that the pathology is mostly 
affecting females without prevalence in any racial or ethnic group (Percy and Lane, 
2013), leading to the hypothesis that the syndrome was due to a dominant X-linked 
mutation, permitting survival only of heterozygous females, while resulting lethal for 
males. Few years later, RTT was linked to mutations of the X-linked MECP2 gene 
(Amir et al., 1999), that alone explain more than 95% of classic RTT cases. 
Due to the severity of symptoms, usually, patients do not reproduce, thus the 
syndrome is sporadic in 99% of cases; few exceptions are represented by 
mechanisms of skewed X chromosome inactivation (which is normally around 50% 
for each allele, while in these cases could be unbalanced 70-80% towards the 
mutated allele) that generates girls without strong symptoms, due to a “dilution” of 
the mutated allele. Unfortunately, these girls may reproduce generating children that 
inherit the mutation, but not the pattern of X chromosome inactivation, thus 
manifesting the syndrome with its common progression (Lombardi et al., 2015).  
To further explain the preponderance of feminine cases in RTT, it was demonstrated 
that generally the disease-causing mutations occur mainly in the paternal germline, 
from which females inherit directly one of the X chromosomes. More rarely, when 
the mutation is in the maternal germline, it could lead to the classical RTT in females 
or to a much more severe condition in males, which usually causes death in the first 
two years of life and often is not even recognized as RTT, but generally defined as 
encephalopathy. In few cases, males manifest a form of RTT compatible with life 
when inheriting a mutation that do not generate a complete loss of function of the 
protein or in a Klinefelter (XXY) background with one of the two X chromosome 
mutated (Lyst and Bird, 2015; Trappe et al., 2001).  
The diagnosis of RTT can be difficult due to the variety of symptoms; nowadays, it 
is based on internationally accepted diagnostic criteria (Smeets et al., 2012) followed 
by molecular genetic testing. Importantly, the genetic alteration of MECP2 alone, 
even if necessary, is not sufficient for the RTT diagnosis, as MECP2 modifications 
are known to be present in a large group of cognitive deficits (like Angelman-like 
	 7	
syndrome, nonsyndromic mental retardation and schizophrenia) (Percy and Lane, 
2013; Smeets et al., 2012). 
 
1.3 The Methyl-CpG-binding Protein 2 (MeCP2) 
 
MECP2 is located on the X chromosome (region q28) and consists of 4 exons 
occupying a region of 76 kb, encoding for the Methyl-CpG binding protein 2 
(MeCP2). Due to alternative splicing, two different isoforms of the protein are 
generated: MeCP2-e1 is the longer one and contains 21 unique N-terminal amino 
acids, is encoded starting from the exon1 and skipping 9 residues on the exon 2 (498 
aa); MeCP2-e2 is encoded starting from the exon 2 and contains 9 unique amino 
acids (486 aa) (Fig. 1.2). The two isoforms are considered functionally equivalent, as 
all the known MECP2 mutations are in the common region, but the isoform e1 is 
predominantly expressed in the brain (Bedogni et al., 2014; Kerr et al., 2012).  
 
 
Figure 1.2 MECP2 structure and splice variants. The MECP2 gene is formed by 4 exons coding for two 
different MeCP2 variants. MeCP2-e1 is the longest one (498aa) and is transcribed starting from exon 1 and 
skipping exon2. MeCP2-e2 transcription (486aa) starts from exon 2 (Bedogni et al., 2014). 
 
As depicted in figure 1.3, the protein can be divided in 5 structural domains: the N-
terminal Domain (NTD, 1-78 aa), the Methyl-CpG Binding Domain (MBD, 79-162 
aa), the Intervening Domain (ID, 163-206 aa), the Transcription Repression Domain 
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(TRD, 207-310) and the C-Terminal Domain (CTD, 311- 355 aa CTDα and 356-486 
CTDβ). Moreover, other functional domains were identified (Fig. 1.3) including the 
Nuclear Localization Signal (NLS, within the TRD), the WW domain (involved in 
splicing regulation) and two PEST sequences (involved in rapid proteolytic 
degradation) (Bedogni et al., 2014). 
 
 
Figure 1.3 MeCP2 can be divided in different structural and functional domains. MeCP2 structural domains 
are: the N-terminal Domain (NTD), the Methyl-CpG Binding Domain (MBD), the Intervening Domain (ID), the 
Transcription Repression Domain (TRD) and the C-Terminal Domain (CTD). The MeCP2 functional domain 
include: the Nuclear Localization Signal (NLS), the WW domain and two PEST sequences (Bedogni et al., 2014) 
 
MeCP2 was discovered in 1992, through biochemical studies, as a protein that binds 
methylated cytosine (5mC) belonging to CpG dinucleotides (Lewis et al. 1992); 
because of its high abundance in brain it is globally bound across the genome 
(mainly following the distribution of the 5mC; (Skene et al., 2010)). This highly 
specific binding is mediated by the MBD which, interestingly, recognizes the 
methylation-dependent hydration of the major groove of the DNA, rather than the 
cytosine methylation itself (Bedogni et al., 2014). MeCP2 binding to the DNA is far 
more complicated than recognizing exclusively methylated DNA, even if the 
functional meaning of the different bindings still needs to be clarified. Indeed, in the 
brain, it also binds the 5-hydroxymethylcytosine (5hmc) through the MBD (Mellén 
et al., 2012). Moreover, it was demonstrated that MeCP2 contains unspecific binding 
sites (in the ID, TRD and CTD) for unmethylated DNA (Ghosh et al., 2010); it is 
possible that this binding just facilitates the association with methylated CpG 
(Hansen et al., 2010). Recently, it was demonstrated that MeCP2 also interacts with 
CpA dinucleotides; interestingly, this modification is prevalent in neurons and 
accumulates in the same period in which MeCP2 levels drastically increase during 
development, possibly, massively recruiting the protein to chromatin (Guo et al., 
2014).  
Until today, hundreds of RTT pathogenic mutations have been identified. 
Interestingly, only eight point mutations justify almost 70% of RTT cases, the others 
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are explained by small C-terminal deletions or complex chromosomal 
rearrangements. Generally, mutations affecting the NLS or the MBD are associated 
with a severer form of the pathology, while mutations affecting the C-terminal region 
give milder symptoms. Highlighting the importance of the MBD function, roughly 
half of the missense mutations causing RTT are in this domain and impair its binding 
specificity. Thanks to the MBD, the protein localizes mainly at pericentromeric 
heterochromatin (containing highly methylated DNA); if the MBD looses its 
capacity to bind 5mC the protein appears diffused into the nucleus. Although less 
frequent, many RTT causing mutations occur in the CTD or the ID, therefore 
highlighting also the relevance of these domains for the correct function of the 
protein (Bedogni et al., 2014; Bellini et al., 2014; Chahrour & Zoghbi, 2007). 
 
1.4 MeCP2: a multifunctional protein  
 
MeCP2 has a role in many different cellular processes, possibly explaining the huge 
variety of symptoms generated by its absence (Fig. 1.4). The MeCP2 structure itself 
suggests that it is a multifunctional protein. Indeed, only the MBD seems to have a 
defined structure, while almost 60% of the protein is unstructured and may assume 
different conformations interacting with different molecules that modify or regulate 
its activity (Bedogni et al., 2014).  
Given the presence of the TRD (the smallest portion of the protein indispensable to 
have transcriptional repression in vitro), one of the first roles attributed to Mecp2 
was as transcriptional repressor. Indeed, it was demonstrated that Mecp2 interacts 
with co-repressor complexes (such as SIN3A (Nan et al., 1998) or NCoR-SMRT 
(Stancheva et al., 2003)) containing histone deacetylase (HDAC) activities. The 
recruitment on the DNA of chromatin remodelling factors (such as HDAC) led to the 
hypothesis that Mecp2 exerts its repressive function through chromatin structure 
compaction rather than working as a classical transcription factor, which target 
specifically single genes. Indeed, it was demonstrated that, in neurons, where Mecp2 
is highly abundant, it binds at the level of the linker DNA and it is able to displace 
H1, condensing the chromatin structure and globally reducing transcription. 
Reinforcing this theory, neurons present high levels of Mecp2, but only half of the 
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quantity of histone H1 compared to other cellular types, suggesting that Mecp2 could 
functionally substitute this linker histone. Accordingly, it was demonstrated that 
neurons lacking Mecp2 present defects at the level of higher-order chromatin 
structure, increased levels of histone H1 and of histone acetylation (Kernohan et al., 
2014; Lombardi et al., 2015; Skene et al., 2010). Moreover, the absence of Mecp2 in 
neurons generates an elevated transcriptional noise due to the lack of repression of 
repetitive sequences and L1 retrotransposons.  
The fact that these effects are neuron specific suggests that Mecp2 function depends 
on its abundance (Muotri et al., 2010; Skene et al., 2010). 
Further complicating the role of Mecp2, some data suggest that MeCP2 might also 
activate transcription. Indeed, Chahrour et al reported that cells lacking Mecp2 
present more down-regulated genes than up-regulated; the authors suggested that 
these activating functions are mediated by the capability of Mecp2 to recruit on the 
DNA the transcriptional factor CREB1 (cyclic AMP-responsive element binding 
protein 1) (Chahrour et al., 2008). The capability of MeCP2 to bind 5hmC, an 
epigenetic signal associated with gene activity (Mellén et al., 2012), further suggests 
a role for Mecp2 in transcriptional activation. Thus, the precise role of MeCP2 in 
regulating transcription remains badly defined, and it is highly possible that it 
depends on the gene locus bound and on its interactions (Bedogni et al., 2014; Lyst 
& Bird, 2015). 
In addition it has been proposed that Mecp2 may regulate gene expression either 
through its capability to bind RNA (Jeffery and Nakielny, 2004) or through its 
interaction with proteins involved in splicing such as YB1 (Y box-binding protein; a 
transcription factor regulating alternative splicing (Young et al., 2005)) and Prpf3 
(pre-mRNA processing factor 3; a spliceosome associated protein; (Long et al., 
2013)). Since Mecp2 deficiency causes the up regulation of different miRNAs, a role 
in miRNA processing has also been proposed (Cheng et al., 2014); this function is 
probably occurring through the interaction of Mecp2 with DGCR8 (DiGeorge 
Syndrome Critical Region 8; subunit of the complex mediating the biogenesis of 
miRNAs), impeding its communication with Drosha. 
Finally, it was demonstrated that Mecp2 regulates the protein synthesis. Indeed, its 
absence causes the reduction of the AKT/mTOR signaling significantly impairing 
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translation (Ricciardi et al., 2011), while the enhancement of the protein synthesis 
ameliorates the phenotype of neurons lacking Mecp2 (Y. Li et al., 2013). 
 
 
Figure 1.4 MeCP2 as a multifunctional protein. Through years many different functions of MeCP2 have been 
discovered. Nowadays the most accepted functions of the protein are involved in: chromatin compaction, 
repression and activation of transcription, alternative splicing, miRNA processing and protein synthesis (modified 
from Lombardi et al. 2015). 
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It is generally accepted that MeCP2 functions are also tuned by different types of 
post-translational modifications (PTM) that modify its binding to DNA/chromatin 
and/or its interaction with other molecules. Indeed, MeCP2 can be phosphorylated, 
acetylated, methylated, ubiquitinated and sumoylated; of note, the significance of 
most of these modifications is still unknown. Phosphorylation represents the PTM of 
MeCP2 best characterized; it can occur at different levels and can affect gene 
expression, adaptation to stimuli and interaction with partners (Bellini et al., 2014). 
The first evidence of Mecp2 phosphorylation was on serine 421 (S421) and it was 
linked to neuronal activity. Indeed, it was demonstrated that Mecp2 normally sits on 
the BDNF promoter and, as a consequence of neuronal membrane depolarization, is 
phosphorylated on S421; the phosphorylation event causes the detachment of the 
protein from the promoter and the consequent transcription of Bdnf (Brain-Derived 
Neurotrophic Factor). Interestingly, this modification is neuronal specific and, 
through the use of knock in mouse lines bearing a phosphodefective mutation in the 
S421 site (S421A), it was demonstrated that it is important for the dendritic growth 
and the development of circuits (Bellini et al., 2014; Chen et al., 2003). 
Subsequently, it was demonstrated that neuronal activity also induces the 
phosphorylation of S424 and a knock in mouse line, harbouring the non-
phoshporylatable mutations S421A and S424A was generated. These mice do not 
show any strong phenotype; surprisingly, they seem to perform better in different 
behavioural tests, confirming that the MeCP2 phosphorylation can affect the 
functionality of the nervous system (Li et al. 2013). Another well-studied 
phosphorylation of Mecp2 is the one that occurs on S80. It is typical of resting 
neurons and gets removed upon neuronal stimulation; functionally, it appears to 
increase the affinity of Mecp2 for chromatin. Although the phosphorylation of S80 
appears as the most abundant, the phosphodefective S80A knock in mouse, 
generated to study this modification, only manifests a subtle weight increase and a 
decreased locomotor activity (Tao et al., 2009). The importance of Mecp2 
phosphorylation has been recently strengthened by the study of the one on threonine 
308 (T308); indeed, the phosphodefective T308A knock in mouse model manifests 
strong symptoms typical of RTT mice. It was demonstrated that the modification of 
this residue abolishes the interaction of Mecp2 with NCoR, reducing the 
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transcriptional repression normally mediated by this complex (Ebert et al., 2013; 
Moretti et al., 2006). Many more phosphorylated sites have been recently mapped, 
but the great majority of them have not been characterized yet. We believe that the 
discovery of pathogenic point mutations on phosphorylation sites will not only 
highlight the importance of these modifications, but might also lead to novel 
information on Mecp2 functioning (Bellini et al., 2014). Accordingly, the 
identification of a RTT patient carrying a phosphomimetic mutation of Tyrosine 120 
(Y120D) led to the careful analyse of this phosphorylation site permitting to 
demonstrate a novel localization and functional association of the methyl binding 
protein with the centrosome (Bergo et al., 2015). 
In conclusion, it is possible that Mecp2 exerts different functions in different cellular 
types, depending on its abundance, on the genomic area bound, on post-translational 
modifications and sensing the cellular specific levels and patterns of DNA 
methylation. Further increasing the complexity of the activity of MeCP2, the 
different post-translational modifications may be independent one from each other or 
may combine in a complex cross talk regulating its functions (Bellini et al., 2014). 
 
1.5 Rett syndrome animal models 
 
Great achievements for the comprehension of Mecp2 functions derive from the 
generation of transgenic mouse models; here we will revise the most significant for 
the study presented in this work.  
In 2001 two independent laboratories produced two different Mecp2 knock out (ko) 
animals. The first one (Mecp2tm1.1Bird ) was generated on a C57BL/6 background 
deleting exons 3 and 4 of the Mecp2 gene, thus removing most of the coding portion 
(with the exception of the N-terminal amino acids) (Guy et al., 2001). While, Dr 
Jeanisch and colleagues produced an animal (Mecp2Jae) devoid only of exon 3 
(including the great majority of the MBD) on a mixed genetic background (129, 
C57BL/6 and BALB/c) (Chen et al., 2001). Both these mouse lines are considered 
valid models for the study of RTT, since they manifest many of the major symptoms 
characterizing the pathology in humans. Importantly, the two models are quite 
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similar, presenting an overlapping progression of symptoms and the same life span; 
thus from now on we will generically talk of the Mecp2 ko.  
Importantly, in the RTT field, it is accepted the use of the male ko mouse as the main 
model of the syndrome. Indeed, the unpredictability of the X chromosome 
inactivation pattern generates a not reproducible phenotype in heterozygous females. 
Furthermore, because of the Mecp2 ko male sterility, mouse females are precious to 
maintain the colony. 
Hemizygous Mecp2 ko mice appear normal at birth and for the subsequent 3-5 
weeks, after which they progressively develop several neurological impairments and 
die 2-4 weeks later. Symptomatic hemizygous males show reduced movements and 
weight, abnormal gait, hind limb clasping, tremors and poor general conditions. The 
expected lifespan is approximately 7-10 weeks (Chen et al., 2001; Guy et al., 2001).  
Importantly, as already mentioned, the ko male mice are sterile; thus, is not possible 
to generate ko females and in order to maintain the colony is necessary to breed 
heterozygous females with wt males. This mating condition generates only 25% of 
ko animals per litter that, together with the small number of animals per litter 
normally produced by C57BL/6 animals, represent a major issue when collecting 
animals for experimental procedures. Moreover, managing these animals is 
particularly challenging as the phenotype of null males tends to deteriorate as the 
colony ages, hardening the detection of symptoms directly ascribable to the absence 
of Mecp2 and not to the general bad conditions of the animals. Lastly, heterozygous 
females are very aggressive and often cannibalize their litter and/or take less care of 
pups, generating detrimental effects on the phenotype of the progeny. To reduce 
these difficulties of colony management many studies in the RTT field have been 
performed on mixed backgrounds. In our laboratory we transferred the Mecp2tm1.1Bird 
genetic modification on the outbred CD1 (ICR) background. We hypothesized that 
this background could, at least partially, solve the presented issues thanks to the 
robustness of these animals and to the their tendency to produce large litters 
(Aldinger et al., 2009). Indeed, the first advantage we observed is the drastic 
increment of the number of pups per litter (which almost double compared to the 
C57BL/6 colony), obviously increasing the number of ko animals obtained from 
single crossings. Interestingly, females take better care of their progeny, as the 
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number of cannibalized litters is incredibly reduced. Mice were tested to evaluate the 
development of the typical RTT phenotype (Fig. 1.5) and, as expected, they manifest 
all the main symptoms (tremors, reduced mobility and hind limb clasping) of the 
C57BL/6 ko animals, approximately in the same time window. Interestingly, the life 
span of the CD1 ko is prolonged as the peak of mortality is around P70-80. We 
concluded that the RTT CD1 mouse is a good model for the pathology and, being 
easier to maintain and manage compared to C57BL/6 animals, it represents an 
improvement for the RTT field (Cobolli Gigli et al., under final review). 
 
 
Figure 1.5 The Mecp2tm1.1Bird modification was transferred on the CD1 genetic background. The plot 
represents the average life span of CD1 null animals compared to wt controls. Arrows represent the timing of 
appearance of the different symptoms typical of the C57BL/6 mice (dotted lines = 50-99% of animals have the 
given symptom, continuous line = 100% of the animals have the symptom) (Cobolli Gigli et al., under final 
revision). 
 
1.6 The central role of the brain in RTT pathogenesis 
 
Although Mecp2 expression is ubiquitous in the body, RTT patients and mice are 
mainly characterized by neurological symptoms, suggesting that the brain may have 
a central role in RTT pathogenesis. To evaluate the involvement of the central 
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nervous system in the development of the phenotype, different groups produced 
mouse models, lacking Mecp2 expression exclusively from the brain, exploiting the 
Cre/loxP technology. At first, Mecp2 expression was removed specifically from 
neurons and glial cells, since their precursor stage (Nestin positive cells), obtaining a 
brain completely devoid of Mecp2 expression starting from the embryonic day 10. 
Interestingly, the phenotype of these mice resulted mainly undistinguishable from the 
one of the Mecp2 total ko animals, demonstrating for the first time that RTT 
symptoms are mainly ascribable to the lack of Mecp2 from the brain (Chen et al., 
2001; Guy et al., 2001).  
Subsequently, given that children were considered normal at birth and symptoms 
became evident after 6-18 months of life, it was evaluated whether the deletion of 
Mecp2 only from post-natal neurons was sufficient to cause the phenotype. A mouse 
model in which Mecp2 expression is ablated only in CamkIIα positive neurons was 
thus generated; CamKIIα starts to be expressed postnatally at low levels (P1) and its 
levels considerably increase with neuronal maturity, meaning that Mecp2 would be 
correctly expressed throughout the entire embryonic development. Interestingly, 
these mice manifested a phenotype similar to the one of the total ko mice, but 
delayed (starting around 3 months of life) and less severe. This result demonstrated 
that Mecp2 has a role in postnatal neurons, as the removal of it from these cells 
generates a RTT-like syndrome. Moreover, the syndrome is mainly ascribable to the 
removal from neurons rather than from glial cells, that in this model correctly 
express Mecp2 (Chen et al., 2001).  
Surprisingly, given the proved central role of the brain in RTT pathogenesis and the 
severity of the neurological symptoms developed by RTT patients, there are no big 
impairments in the morphology of the brain. Blood vessels, cranial nerves, gyri, 
basal ganglia, cerebellum, brain stem and spinal cord are not altered and there are no 
signs of degeneration or inflammation. The main characteristic of the RTT brains is 
the reduced head circumference, due to a decrement in brain size and weight, with a 
particularly evident effect in the prefrontal, posterior frontal and anterior temporal 
regions. The diminished dimension of the brain is ascribable to a reduction of the 
neuronal soma size and to an increment in cell density, while the total number of 
neurons does not change. Moreover, RTT brains are characterized by decreased 
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spine density and dendritic arborisation in both the hippocampus and the cortex; in 
some cases hypoplasia of corpus callosum was also observed (Armstrong et al., 
2003; Bauman et al., 1995; Kishi and Macklis, 2004).  
The morphology of the RTT brain was further and deeply investigated using animal 
models. Most of the impairments recognized in RTT patients were also found in the 
Mecp2 hemyzigous male mice. Indeed, these animals are characterized by a reduced 
thickness of the cerebral cortex (roughly 20% less than wt controls), due to the 
diminished neuronal soma size and the increased cellular density. Moreover, the 
dendritic arborisation is poorly developed, with a reduction of the number of spines 
and synapses both in young “pre-symptomatic” and adult symptomatic mice 
(Belichenko et al., 2009; Chao et al., 2007; Fukuda et al., 2005; Kishi and Macklis, 
2004). Importantly, the impairments in synaptic formation and maturation may lead 
to alterations in cerebral plasticity. Thus, many groups evaluated the correct 
functioning of impulses transmission and synaptic plasticity in order to link 
structural phenotypes to changes in physiology, possibly explaining some RTT 
features. It was demonstrated that pyramidal neurons, deriving from the layer 5 of 
the somatosensory cortex of Mecp2 ko animals, display reduced spontaneous activity 
at both “pre-symptomatic” (second postnatal week) and early symptomatic stages. 
Moreover, RTT brains are characterized by the unbalance between cortical excitation 
and inhibition in favour of the second one; indeed, despite cells intrinsic excitability 
is normal, the total excitatory synaptic drive decreases, while the total inhibitory 
drive increases. The incorrect balance between excitation and inhibition may cause 
deficits in learning and memory in RTT patients (Dani et al., 2005).  
To further characterize the mechanisms underlying these alterations, the synaptic 
output was analysed (measuring the action-potential-evoked excitatory postsynaptic 
currents; EPSCs), resulting reduced in null neurons and enhanced in neurons over-
expressing Mecp2, leading to the conclusion that Mecp2 regulates the magnitude of 
the synaptic output. The cause of this impairment was determined as a modification 
in the glutamatergic synapses number; indeed, the absence of Mecp2 leads to the loss 
of glutamatergic synapses, while its over-expression leads to an increment of them. 
This impairment was highlighted in vitro on glutamatergic neurons, but also in vivo 
on 2-weeks old mice, suggesting that Mecp2 has a fundamental role in the initial 
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formation of synaptic contacts during the early post-natal phases of neuronal 
development (Chao et al., 2007).  
Further strengthening the role of Mecp2 in regulating synaptic plasticity, a mouse 
model presenting the truncation of the protein in position 308 shows impaired Long 
Term Potentiation (LTP) and Depression (LTD) mechanisms (Moretti et al., 2006), 
while a mouse model that over-express Mecp2 shows enhanced LTP (Collins et al., 
2004).  
To better characterize the role of Mecp2 in the brain and to evaluate the involvement 
of the different brain areas in the development of the phenotype, many mouse models 
lacking Mecp2 expression in precise brain districts were produced. For example, 
mice lacking Mecp2 selectively from the basolateral-amygdala (Adachi et al., 2009), 
the hypothalamus (Fyffe et al., 2008), dopaminergic and noradrenergic neurons 
(Samaco et al., 2009), or the GABA releasing neurons were generated (Chao et al., 
2010). Interestingly, all these animals develop some aspects of RTT syndrome 
suggesting that RTT neurological traits are the sum of effects deriving from the 
malfunctioning of many, if not all, the different brain areas. 
 
1.7 Is Mecp2 involved in pre-natal development or in neuronal 
maintenance? 
 
Nowadays, it is still unclear since when the expression of Mecp2 is necessary for the 
correct neuronal functioning: whether starting from the first phases of neuronal 
development or whether exclusively for neuronal maintenance of mature cells.  
Guy et al. investigated the role of Mecp2 in adulthood, through the reactivation of 
Mecp2 expression in Mecp2 ko animals. Indeed, they generated a mouse line in 
which Mecp2 expression is silenced by a stop codon flanked by a loxP cassette, that 
can be removed by the expression of a ubiquitous Cre (bound to the estrogens 
receptor) activated by Tamoxifen (estrogens analogue) administration. The 
controlled injection of Tamoxifen to young adult mice (3-4 weeks old) induced the 
re-expression of, which mediated the elongation of survival and the global reduction 
of symptoms, therefore, demonstrating the reversibility of Mecp2-associated 
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symptoms, at least in mice (Guy et al., 2007). Nevertheless, this result did not clarify 
whether Mecp2 has a role in neuronal maintenance as adult neurons, lacking Mecp2 
since early developmental phases, may not be properly mature (Guy et al., 2007).  
To evaluate if the entity of the rescue induced by Mecp2 re-expression depends from 
the timing of re-expression, females harbouring a floxed stop cassette in the Mecp2 
gene were crossed with males expressing Cre under different promoters (Nestin, Tau 
and CamKIIα) that are activated in neurons at different developmental stages. 
Indeed, under the Nestin promoter, Cre starts to be expressed around E10 in neuronal 
and glial precursors; the Tau promoter is activated in post-mitotic neurons 
immediately after the exit from the cell cycle (still in the embryo), while the 
CamKIIα promoter is activated in neurons postnatally. Interestingly, when Mecp2 is 
re-expressed starting from early embryonic stages (Nestin and Tau promoters) the 
life span of the animals almost doubles compared to the ko. The rescue mediated by 
these promoters is almost undistinguishable, suggesting that RTT phenotype is 
mainly due to the lack of Mecp2 in neurons, rather than in glial cells. On the 
contrary, when re-activating Mecp2 expression in the post-natal brain (CamKIIα 
promoters) the increment of the life span is minimal (even if significant), further 
confirming that Mecp2 has a role in post-natal neurons, as the re-expression of 
Mecp2 in CamKIIα positive cells ameliorates the phenotype. However, the protein 
may exert important functions even during the pre-natal neuronal development, as 
the benefit obtained from the re-expression at earlier developmental time points is 
much more evident (Giacometti et al., 2007). This is in line with the previously 
reported study, in which mice lacking Mecp2 in Nestin positive cells since the first 
phases of neurogenesis (E10) developed stronger symptoms than the animals lacking 
it only from CamKIIα positive post-natal neurons (P1). Thus, the role of Mecp2 
during pre-natal development is still debated, but its participation to these early 
phases is supported by growing evidences demonstrating that children and mice 
manifest subtle, but consistent, signs of the pathology in the so called “pre-
symptomatic” stage, immediately after birth (Fehr et al., 2011; Nomura, 2005; 
Santos et al., 2006). Indeed, from retrospective analysis of children’s first infancy, it 
was demonstrated that often RTT patients develop some behavioural abnormalities 
and muscle hypotonia before the overt onset of symptoms, together with a 
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disturbance of the sleep-wake rhythm. Moreover these children are often described 
as overly calm, or placid and have difficulties in rolling, crawling or pulling to stand 
(Fehr et al., 2011; Nomura, 2005). Analysing data deriving from 120 RTT affected 
girls, it was demonstrated that, at birth, they present a reduced occipito-frontal 
circumference, shorter length and lower weight (Huppke et al., 2003). Moreover, 
important evidences derive from RTT males that usually manifest strong signs of 
neurological dysfunction already at birth, suggesting that embryonic development 
could be somehow impaired when Mecp2 is absent (Smeets et al., 2012).  
Alterations in the first post-natal period were also identified in mice, as ko animals 
display an increment of ultrasonic vocalizations (after separation from the mother) 
during the first week of life (compared to wt littermates) (Picker et al., 2006). 
Besides, another study highlighted that different parameters of maturation (as body 
weight and postural reflexes) are impaired in the pre-weaning period in null mice 
compared to wt littermates. Furthermore, the alteration of synapses, the reduced 
spontaneous activity and the diminished number of glutamatergic synapses 
previously described, appears early in post-natal development, during the “pre-
symptomatic” phase (Chao et al., 2007; Dani et al., 2005). It would be of interest 
verifying whether these early alterations are ascribable to impairments of 
neurogenesis and/or maturation during the embryonic development. A first hint 
suggesting that Mecp2 may have a role since the first phases of generation and 
maturation of neurons derived from a study of Smrt et al., investigating adult 
neurogenesis in the dentate gyrus of the hippocampus. They demonstrated that this 
process, that resembles the embryonic cortical neurogenesis (starting from a Neural 
Precursor Cell (NPC), which asymmetrically divides, generating an immature neuron 
and another precursor), is altered when Mecp2 is absent, producing neurons that do 
not mature correctly (Smrt et al., 2007).  
Through years, the few studies of the embryonic neuronal development in the RTT 
field focused mainly on cerebral cortex, probably because impairments in cortical 
morphology are one of the main features of RTT mice and patients (Armstrong, 
2005; Fukuda et al., 2005). Moreover, RTT is characterized by strong cognitive 
deficits and, in some cases, by seizures that are mainly ascribable to cortical 
alterations (Smeets et al., 2012). Many groups agreed that Mecp2 expression in the 
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developing cerebral cortex follows neuronal maturation in mice, being detectable in 
early post-mitotic neurons reaching their final position in the cortex (Kishi & 
Macklis, 2004; Schmid et al., 2008; Shahbazian., 2002). Indeed, the protein was 
detected as early as at E12, but only in Cajal-Retzius (CR) cells, which are among 
the first neurons produced in the embryonic cortex. Later on in neurogenesis, Mecp2 
is widely expressed by post-mitotic neurons residing in the entire Cortical Plate (CP). 
These works agreed on the lack of Mecp2 expression in progenitors populating the 
apical area of the developing cortex (Kishi & Macklis, 2004; Schmid et al., 2008; 
Shahbazian., 2002). Partially in contrast with this pattern of expression, it has been 
shown that a small proportion of progenitors (Nestin+) do express Mecp2 in rat 
embryonic cortex at E14 (Jung et al., 2003) and that it is expressed during all the 
phases of the central nervous system development in Xenopus and chicken embryos 
(Petazzi et al., 2014; Stancheva et al., 2003). More recently, in vitro experiments 
using neuroprogenitors (NPCs) and neural stem cells (NSCs) demonstrated that these 
cycling progenitors (Caballero., 2009; Okabe et al., 2010) and also adult NPCs in 
vivo (Li et al., 2014) do express Mecp2. All these evidences together did not produce 
a clear and definitive picture of whether and when Mecp2 is expressed during early 
corticogenesis. Thus, the real expression pattern of Mecp2 in the developing cortex 
should be better analysed; Mecp2 expression in cortical progenitors might suggest 
relevant functions even in the first phases of neurogenesis, when cells are still 
cycling. 
 
1.8 Mecp2 and cellular proliferation 
 
The role of MeCP2 in cell growth has been partially investigated in the past. The first 
evidence suggesting that MeCP2 expression influences cell proliferation dates back 
to 2002, when Balmer et al. performed single cell cloning of T lymphocytes, derived 
from heterozygous patients, segregating cells that correctly expressed the protein 
from the mutated ones. Surprisingly, they obtained a strongly reduced frequency of 
clones harbouring the MECP2 mutation compared to the wt ones, concluding that 
although MeCP2 expression is not necessary for T lymphocytes survival, its absence 
is a disadvantage for cells growth (Balmer et al., 2002). Accordingly, the lack of 
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MeCP2 expression (obtained through the use of siRNAs directed towards MECP2) 
causes the reduction of cellular proliferation in different non-neuronal cell types, as 
glial cells (Nagai et al., 2005), prostate cells and cancer prostate cells (Bernard et al., 
2006), NIH/3T3 (Babbio et al., 2012), MEF and MRC5 (Bergo et al., 2015). 
Moreover, MECP2 repression has a positive effect on the dimension of cancer, 
reducing cell proliferation, invasion and migration in osteosarcomas (Meng et al., 
2014).  
The first suggestion of a possible mechanism through which MeCP2 could affect the 
cell cycle derives from the study of a post-translational modification of the protein. 
Indeed, the detection of the phosphorylation of Y120 led to the discovery of the 
association of MeCP2 to the centrosome and to the hypothesis that the protein could 
at least partly participate to cell cycle regulation through the interaction with this 
organelle (for example regulating the timing of mitosis, spindle geometry and 
microtubule nucleation). Accordingly, Bergo et al. demonstrated that the cell cycle 
progression of MRC5 resulted altered, when MeCP2 is absent, with the reduction of 
the proportion of cells in G1, and the increase of cells in G2/M. Moreover, MEF cells 
treated with siRNAs against Mecp2 are characterized by an increment of markers of 
mitosis (as pH3 and CyclinB1) and, accordingly, the duration of the mitosis of HeLa 
cells is prolonged (Bergo et al., 2015).  
Given the central role of the brain in RTT pathogenesis, it would be of great interest 
linking the presented defects of cell growth to NPCs, as it is known that the neuronal 
phenotype strictly depends on its progenitorial stage (MuhChyi et al., 2013). 
Strengthening the importance of studying neural precursors, Li et al. demonstrated 
that, in adult NPCs, growth factors induce MeCP2 S421 phosphorylation, suggesting 
that Mecp2 PTM might be involved in cell proliferation. Indeed, a phospho-defective 
modification of S421 (S421A) causes reduced proliferation and an increased 
differentiation. Since no specific cell cycle phase was found affected, the authors 
suggest that this phenotype is related to the downregulation of the Notch signaling, 
which is normally downstream to this phosphorylation event. This work 
demonstrated, for the first time, that Mecp2 has a role in regulating the balance 
between proliferation and differentiation of adult NPCs; given the similarity of adult 
and embryonic neurogenesis it would be of interest to evaluate these mechanisms in 
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early development (Li et al., 2014). The first and so far unique study evaluating if 
Mecp2 expression affects embryonic neurogenesis, starting from cycling progenitors, 
was performed on chicken embryos. The over-expression (through in utero 
electroporation) of Mecp2 in the neural tube induces the reduction of the thickness of 
it after 48 hours, at a developmental stage (HH10) in which cells are mainly 
mitotically active progenitors. In agreement with an unbalance of proliferation and 
differentiation suggested by studies on aNPCs, Petazzi et al. highlighted a reduction 
of the number of cycling cells, possibly caused by a precocious differentiation; in 
fact, ectopically positioned neurons were identified. These results suggest that the 
over-expression of Mecp2 reduces the proliferative potential of progenitors and 
promotes differentiation, demonstrating for the first time that Mecp2 have a role in 
early development (Petazzi et al., 2014). 
Overall it appears quite clear that a better investigation on the role of Mecp2 in NPCs 
is deserved, including an analysis on any possible effect on epigenetics. In fact, it is 
well-accepted that the methylation signature of a stem cell, together with other 
epigenetic modifications, determines its progressive cell differentiation, defining 
which cell type is going to mature from a single progenitor; it is easy to speculate 
that in the absence of Mecp2, the methylation of the DNA is not properly read and 
cells do not correctly mature (MacDonald and Roskams, 2009; MuhChyi et al., 
2013). 
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2. MATERIALS and METHODS 
 
2.1 Animals and tissues 
 
The Mecp2 mouse strain was originally purchased from Jackson Laboratories 
(003890 B6.129P2(C)-Mecp2<tm1.1Bird>/J). This strain, generated by Dr. Adrian 
Bird (Guy et al., 2001), is particularly poor in terms of progeny (heterozygous 
females are not too prone to feed and take care of pups, therefore are often replaced 
by foster mothers) and fairly difficult to maintain (ko male mice are sterile). 
Therefore, we bred heterozygous females with CD1 male mice, this backcrossing 
strategy was used until the 10th generation, after which the genetic background is 
usually considered clean enough for molecular testing. Ko mice on a clean CD1 
background recapitulate the typical phenotype of the regular C57/BL6 original mice, 
with the advantage of having a larger progeny. Mice genotypes were analyzed 
through PCR on genomic DNA purified from tails. For the identification of the ko 
allele the forward primer was: 5’-ACCTAGCCTGCCTGTACTTT-3’, while for the 
WT allele was: 5’-GACTGAAGTTACAGATGGTTGTG-3’ and the reverse primer 
was 5’-CCACCCTCCAGTTTGGTTTA-3’ (Miralvès et al., 2007). For the PCR 
amplification an incubation sequence of 30 seconds at 95°C, 30 seconds at 60°C and 
40 seconds at 72°C was repeated for 35 cycles followed by a final incubation at 72°C 
for 7 minutes. The PCR product obtained was a single band of 450 base pairs (bp) 
for the ko, a single band of 400 bp for the wt and the two bands together for 
heterozygous animals. 
Time pregnant females were generated by crossing overnight wt CD1 males with 
Mecp2 heterozygous (−/+) CD1 females, the day of vaginal plug was considered 
E0.5. When needed, BrdU (30 mg/Kg) was intraperitoneally injected in time 
pregnant females at E14.5 and embryos were collected 24 hours later (E15.5). 
Tissues generated for microarray and RNA studies were dissected out of E15.5 
embryos collected from anesthetized (Avertin, Sigma Aldrich) pregnant females, 
rapidly frozen on dry ice and stored at −80°C for future experiments. Embryos 
dedicated to histology were transcardially perfused with 5 ml 4% PFA under a 
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dissection microscope and post fixed in 4% PFA for additional 4 hours; 
cryoprotected overnight at 4°C in 30% sucrose, then embedded in Optimal Cutting 
Temperature (OCT) and kept at –80°C until sectioning. 12 μm sections were 
generated by slicing the tissues with a cryostat (Leica), sections were then stored at 
−20°C until further analysis. 
All procedures were performed in accordance with the European Community 
Council Directive 86/609/EEC for care and use of experimental animals; all the 
protocols were approved by the Italian Minister for Scientific Research and by the 
local Animal Care Committee. 
 
2.2 Histology, immunofluorescence and immunohistochemistry  
 
As a general procedure, mounted, 12μm thick brain sections were washed in PBS 
and incubated for 1 hour in blocking solution (10% horse serum, 0.1% tritonX-100, 
PBS). In cases when antigen retrieval steps were necessary, samples were boiled in 
0,01M Sodium Citrate pH 6,4, then washed in PBS, 10 min in 1% TritonX-100 (or 
PBS with Tween20 (1:1000) (PBST)) and 30 min in 0,1M Glycin. For the BrdU 
staining tissues were treated with HCl 1N at 37°C for 30 min, or with DNase (1 
μg/ml, Roche, 11284932001) diluted in the blocking solution. Tissues were then 
incubated with the primary antibody diluted in blocking solution overnight at 4°C. 
Primary antibodies were used at the following concentrations: anti-Mecp2 (Sigma-
Aldrich, 1:1000, rabbit), anti-Mecp2 (Cell signalling, 1:200, rabbit), anti-Nestin 
(Millipore, 1:200), anti-Tuj1 (Covance, 1:2000, mouse), anti-Reelin (DSHB, 1:20), 
anti-BrdU (Accurate, 1:1000, rat), anti-pH3 (Abcam, 1:3000, mouse), anti-RFP 
(Clontech, 1:500, rabbit), anti-GFP (Molecular Probe, 1:1000, chicken), anti-
CyclinD1 (Neomarkers, 1:200, rabbit), anti-Tbr2 (eBioscence, 1:500, rat), anti-Pax6 
(1:100, rabbit), anti-Ki67 (Vector, 1:100, rabbit), anti-Neun (Chemicon, 1:4000, 
mouse), anti-NeuroD1 (Santa Cruz, 1:50, goat). The day after, slices were washed 
for roughly 2 hours in PBS and, for the immunofluorescence, incubated for 1 hour 
with the secondary antibody (Alexafluor, Invitrogen, Molecular Probes) diluted 
(1:500) in blocking solution. Sections were then washed in PBS and incubated with 
DAPI (Invitrogen, 0,1 mg/ml in PBS) for 10 min, before mounting in Prolong Gold 
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(Invitrogen). For the immunohistochemistry, slices were incubated with the 
secondary biotinylated antibody (1:500, Vector Laboratory) diluted in blocking 
solution for 1 hour and treated with the Vector ABC kit (Vectastain) followed by 
staining with the Vector VIP peroxidase substrate kit. Sections were mounted with 
the DPX mountant. 
Nikon microscope, objectives and software were used for the imaging of figure 1; 
Confocal Leica microscope, objectives and software was used for all the other 
figures. Panels were composed into figures using Adobe Photoshop. 
For the measurement of the CyclinD1 intensity images were analyzed with ImageJ 
setting 3 different levels of threshold. Cells that resulted above the threshold were 
manually counted. An investigator blinded to the experiment counted all the cells. 
 
2.3 Neurosphere generation  
 
Timed-gestation female mice were anesthetized with Avertin to obtain E15.5 mouse 
embryos. The following procedure to generate Neural Progenitor Cells (NPCs) 
culture was first described by Gritti et al. and Magri et al. (Gritti et al., 1996; Magri 
et al., 2011). Briefly, embryos were individually dissected in PBS and the neocortex 
was transferred in Dulbecco’s Modified Eagle Medium/F12 (DMEM/F12) and 
dissociated by extensive enzymatic digestion with Papaine (Sigma) and DNase (0,1 
mg/ml, Roche, 11284932001), followed by mechanical trituration (using a pipette) 
till no residual tissue was anymore visible. Cells were then grown in complete 
medium (DMEM/F12, 30% Glucose, 7,5% NaHCO3, 1% L-Glutamine, 1% 
Pen/Strep, 2mg/ml Heparin, Hormone Mix, 20 ng/ml Epidermal Growth Factor 
(EGF), 10 ng/ml basic Fibroblast Growth Factor (bFGF)), in which cells 
spontaneously form neurospheres (Gritti et al., 1996). Neurospheres were then 
dissociated in single cell cultures, plated on matrigel-coated coverslips and fixed 
with 4% PFA to produce samples to be analyzed by immunofluorescence 
experiments.  
For the neurosphere generation assay 100 singles cells were re-suspended in 100 μl 
of complete medium in a well of a 96-well plate. After 3 days the generation of 
spheres was evaluated. 
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2.4 Time-lapse imaging 
 
The time-lapse imaging experiments were performed with a Zeiss Axiovert S100 
TV2 microscope. Cells were plated and maintained in complete medium for 48 hours 
at 37°C with 5% CO2, images were taken every 10 minutes. Single cells were then 
analysed for the mitosis duration. 
 
2.5 RNA purification, cDNA synthesis and quantitative PCR 
 
The RNA was extracted either from neurospheres or embryonic cortexes; tissues 
were homogenized in RLT buffer (RNeasy Lysing Buffer from the RNeasy Mini kit, 
Qiagen) using a glass-glass potter, while cells were vigorously resuspended in the 
same buffer; the whole volume was loaded on a RNAeasy mini column (Qiagen), 
following the kit protocol. The RNA was eluted RNA/DNAse free H2O.  
The cDNA synthesis was performed using a QIAGEN kit (RT2 First Strand Kit). The 
qPCR for the intracellular signaling factors (Fig. 10C) was performed using SYBR 
Green (Life Technology) as a fluorescent dye. With the following primers: 
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The qPCR for the glutamatergic receptors and the ionic channels (Fig. 10A, B) 
was performed using the Synaptic Plasticity RT2 Profiler PCR Array and the 
Neuronal Ion Channels RT2 Profiler PCR Array (Qiagen) respectively. 
 
2.6 Microarray 
 
The quality of the RNA extracted from 3 wt and 3 ko E15.5 cortices was assessed 
with the Agilent Bioanalyzer microfluidics-based system (Agilent technologies), 
samples with RNA integrity number lower than 8 were discarded. The gene 
expression of whole transcriptome was performed with the Illumina Direct 
Hybridization Assays according to the standard protocol (Illumina Inc.). For each 
sample 500 ng of total RNA were reverse transcribed according to the Illumina 
TotalPrep RNA Amplification kit (Ambion) and cDNA was generated. Washing, 
staining and hybridization were performed according to the standard Illumina 
protocol; each sample was hybridized onto Illumina MouseRef-8 Expression 
BeadChip arrays. Hybridization and scanning were performed according to the 
manufacturer’s indications on an Illumina iScan System and data were processed 
with GenomeStudio; array data were processed with quantile normalization in 
Genome Studio software before further analysis, average signals were calculated on 
gene-level data according to the standard Illumina detection cutoff (detection p-value 
lower than 0.001). 
 
2.7 Gene Set Enrichment Analysis 
 
At first the GSEA software organizes the genes of the dataset in a ranked list based 
on their expression value, then it determines the distribution of a set of genes (gene 
set) throughout the ranked gene list. To obtain a numerical measurement of the 
representation of a gene set in one experimental group or the other the GSEA 
software calculates an Enrichment Score (ES). The ES increases when a gene 
belonging to a gene set is found in the ranked list, the degree of the increment 
depends on the amplitude of the differential expression. Then the software 
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determines the significance of the ES, by an empirical gene set-based permutation 
test procedure. The gene sets can be custom-made or can be downloaded from the 
Moleculare Signature Database (www.broadinstitute.com).   
 
2.8 Neuronal cultures 
 
Cortexes from E15.5 animals were dissected out and digested with Trypsin 0,25% 
and mechanically dissociated by pipetting. Single cells were plated at low density 
(30.000 cel/well in 6-multiwell plate) on glass coversplip coated with poly-L-lysine 
(0,1 mg/ml). Neurons were grown in culture medium: Neurobasal, B27 (1:50), 
Glutamax 1% and Pen-Strep 1%. 
 
2.9 Calcium imaging 
 
Cortical neurons (from 3 ko and 4 wt animals) were loaded with calcium-sensitive 
dye (10 mM Oregon Green 488 BAPTA-1 AM, Molecular Probes) in Neurobasal 
medium for 1 hour at 37°C. The detection of calcium responses was performed in 
KRH (Krebs’-Ringer’s-Hepes: 125 μM NaCl, 5 μM KCl, 1,2 μM MgSO4, 1,2 μM 
KH2PO4, 15 μM Hepes, 6 μM Glucose, 2 μM CaCl2 at pH 7,4). The stimulation with 
25 μM glutamate was performed in the presence of Nifedipine (20 μM), 
Tetradotoxin (1 μM), and Bicuculline (20 μM) through a perfusion system (Warner 
Instruments, Hamden, CT, USA). The electrical field stimulation was performed in 
the presence of CNQX (20 μM, 6-cyano-7-nitroquinoxaline-2,3-dione), APV (50 
μM, R-2-amino-5-phosphonopentanoate) and Bicuculline (20 μM) using a 
stimulation chamber (Warner Instrument). Calcium transients were induced with a 
stimulus train of 2 seconds (duration 1 ms; amplitude 90 mA) at 30 Hz (Pozzi et al., 
2013) using a train generation unit (Digitimer Ltd, DG2A) connectd to a stimulus 
isolation unit (SIU-102; Warner Instruments). Recording chambers were placed on 
the stage of an IX-71 inverted microscope (Olympus) equipped with an EMCDD 
(electron-multiplying CCD) camera (Quantem 512x512, Photometrics). The 
illumination was obtained using a light-emitting diode single LED (Cairn Research 
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Optoled; 470 nm) and a related GFP filter; Regions of interest (ROIs) of about 15-
pixel diameter (corresponding to ≈12 μm) were drawn on the cell cytoplasm of 
virtually all the cells in the recorded field. Time-lapse recording of calcium dynamics 
was performed with an acquisition rate of 5 Hz for 600 s and off-line analysed with 
the MetaFluor software (Molecular Devices). Calcium responses were measured as 
ΔF (Fmax−F0) with respect to the baseline (F0). A total of 10–15 neurons were 
analysed for each field. Cumulative data were then analysed through Kolmogorov–
Smirnov statistic to verify non-parametric distribution.  
 
2.10 Morphological analysis  
 
Cortical neurons from 3 ko and 4 wt animals were prepared as previously described 
and morphological analyses were performed at DIV3. Dendrites were highlighted 
through the use of the anti-Tuj1 antibody, while the nuclei through the use of DAPI. 
Neurites length was measured only on single neurons, not in contact with other 
neurons, using the NeuronJ plugin of ImageJ. Neurites were considered as the Tuj1 
positive structure starting from the soma. They were classified as long when their 
length was above 100 μm, or short when shorter than 100 μm. The size of the nuclei 
was measured on the DAPI staining using ImageJ. 
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3. RESULTS 
 
Although RTT is considered a neurodevelopment pathology, the function of Mecp2 
has been thoroughly investigated only during late phases of development, possibly 
because children were considered normal at birth. Nowadays, evidences of subtle but 
consistent symptoms in the so-called “pre-symptomatic” phase are growing 
suggesting possible roles of Mecp2 during early phases of development (Chao et al., 
2007; Fehr et al., 2011; Nomura, 2005; Santos et al., 2007). For this reason, and 
given the cortical phenotype affecting both RTT patients and animal models, we 
started investigating the role of Mecp2 during corticogenesis.  
First, we searched for previous evidences of Mecp2 expression in the cortex. 
Different works agreed that Mecp2 expression follows neuronal maturation in mice, 
as it was detected only in early post-mitotic neurons reaching their final position in 
the cortex and not in cycling progenitors (Kishi & Macklis, 2004; Schmid et al., 
2008; Shahbazian., 2002). However, these evidences have been challenged by the 
recent detection of Mecp2 expression in in vitro cultivated cycling cells such as 
NSCs and induced pluripotent cells (IPCs) (Caballero., 2009; Okabe et al., 2010). 
Taken together, these data do not produce a clear and definitive picture of whether 
and when Mecp2 is expressed during early corticogenesis or whether its expression 
is confined to mature neurons only. 
To map Mecp2 expression during cortical development, we stained embryonic 
tissues (using null animals as negative controls) beginning from embryonic day 10.5 
(E10.5, Fig. 3.1a, a’), a time point at which the cortical wall is populated by 
neuroepithelial cells, that, later on, will give rise to the different types of cortical 
NPCs (apical and basal). Such progenitors will, eventually, give birth to the 
glutamatergic neurons populating the cortex (Florio and Huttner, 2014). Stunningly, 
at such time point we were able to detect low but consistent levels of Mecp2, that 
continues to be expressed throughout embryonic cortical development (Fig. 3.1a-c) 
by all cell types: progenitors (Nestin+; Fig. 3.1d), immature/maturing neurons 
(Tuj1+; Fig. 3.1e) and Cajal Retzius cells (CR; Reelin+; Fig. 3.1f). From these 
analyses it is clearly visible that Mecp2 levels are indeed lower in the NPCs 
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compared to mature neurons (Fig. 3.1b), possibly explaining why it was hardly 
detected in this population in the past. 
 
 
Figure 3.1. Mecp2 is expressed by all the cell types composing the developing embryonic cerebral cortex. 
Mecp2 is detectable, at least, starting from E10.5 (a) and continues to be expressed during all the cortical 
development (b: E14.5; c: E18.5), throughout the entire cortical thickness. Ko tissues were used as negative 
controls (a’, b’). All the different cell types expressing Mecp2 were identified through specific markers: Nestin to 
recognize progenitors (d), Tuj1 for neurons (e) and Reelin for CR cells (f). Scale bar: 25 µm in a, a’, d, e, e’, f. 50 
µm in b, b’. 100 µm in c. 10 µm in f’, f’’ (Bedogni et al., 2015). 
 
The discovery that Mecp2 is expressed in the cortex from the earliest phases of 
neurogenesis raised the question of whether and what functions it might play in these 
populations. Given the well-accepted role of Mecp2 as transcriptional regulator, we 
performed a microarray analysis on E15.5 ko cortices compared to wt controls, to 
evaluate the transcriptional perturbations generated by lack of Mecp2. The choice of 
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focusing on E15.5 has different advantages: (i) it corresponds to the peak of 
neurogenesis in mice; indeed, at this time point the cortex is populated by a mixture 
of progenitors, maturing and mature neurons; (ii) E15.5 is a stage at which cells are 
mainly glutamatergic, without glial cells or massive infiltration of GABAergic 
interneurons possibly masking effects driven by the heterogeneity of the different 
cellular populations.  
A first analysis of the transcriptional profile through regular bioanalytical approaches 
did not highlight any particularly strong effect: imposing a fold change cut-off of 1.3, 
we only obtained 270 deregulated genes, that became 11 with a fold change of 2 and 
0 with higher fold changes. Furthermore, applying a p-value threshold of 0.05, 
without fold change cut-offs, only 135 genes resulted differentially expressed (Fig. 3. 
2A). Moreover, the standard gene ontology (GO) analysis did not reveal any solid 
molecular or functional relationships between the modulated genes (Bedogni et al., 
2015). Such results, besides not being particularly informative, are anyway in line 
with the fact that Mecp2, globally binding to methylated sequences, modestly and 
regulates the transcription of the vast majority of genes (Skene et al., 2010). In line 
with this, it is thus not possible to detect strong transcriptional deregulations of single 
genes. Given such a small variation in amplitude, we hypothesized that analysing 
groups of (possibly mildly) deregulated genes rather than single transcripts could be 
more informative. The rationale is that the sum of even mild deregulations affecting 
a statistically significant number of genes of the same group could highlight 
biological effects otherwise masked. The Gene Set Enrichment Analysis (GSEA) 
provides this possibility. The GSEA software considers the entire dataset obtained 
from a microarray analysis without imposing any threshold, as it considers each 
transcriptional variation, even if small in amplitude, that normally would be 
considered “below threshold”. The GSEA focuses on groups of selected genes (gene 
sets) gathered because of common features, such as being part of the same biological 
pathway, and imposes these gene sets on the dataset (previously ordered based on 
expression levels) determining whether they are enriched in one of the two 
conditions (in our case Mecp2 ko or wt; Subramanian et al., 2005). 
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Figure 3.2. E15.5 Mecp2 ko cortices display a mildly deregulated expression profile. Data obtained by the 
microarray analysis of E15.5 cortices were graphed on a volcano plot (A), displaying the statistical significance 
versus the differential expression of genes (fold change). Blue lines represent 1.3 and 2 fold change cut offs; red 
lines correspond to 0.05 and 0.01 p-values. The microarray was analysed using the GSEA with two non-
overlapping custom-made gene sets (B), representing the proliferative and the post-mitotic compartment of the 
cortex. The two gene sets segregate in either the wt or ko samples as highlighted by the MA plot (C; M: 
log2(KO/WT); A: 1/2log2(KOxWT)) and by the GSEA output (D, E) (Bedogni et al., 2015). 
 
At first, we exploited the GSEA software through the creation of two custom-made 
gene sets, composed by the genes sharing the common feature of being expressed by 
cells located in different subareas of the developing cortex. This was made possible 
thanks to the data produced by Ayoub et al. (2011); in their work, in fact, the authors 
determined the gene expression profile of different mouse cortical areas (VZ/SVZ, 
IZ, CP) dissected through laser capture on E14.5 cortexes. In order to clearly 
segregate genes describing either the VZ/SVZ population (cycling progenitors with a 
proliferating identity) or the CP population (maturing/mature neurons with a late 
post-mitotic identity) we applied a fold change cut-off of 20 on the data (Fig. 3.2B). 
At first, by superimposing these two sets of genes on a plot representing the 
amplitude of expression of each gene (A) related to its fold change (M) (MA plot), 
we highlighted a peculiarity in their segregation, as in ko samples the group defining 
the proliferative identity was for the most part up-regulated, while the group defining 
the post mitotic/mature identity was down-regulated (Fig. 3.2C). The GSEA 
confirmed the statistically significance of the enrichment of the proliferation identity 
in the ko samples and the late post-mitotic identity in the wt samples (Fig. 3.2D). We 
interpreted these results hypothesizing that Mecp2 null cells might proceed through 
	 35	
different phases of neurogenesis at a lower rate, therefore delaying the maturation 
process in the ko cortex. Furthermore, to elucidate what molecular mechanisms 
could be deregulated when Mecp2 is absent, we superimposed all the curated gene 
sets, representing canonical pathways collected in the Molecular Signature Database 
(MSigDB, version 3.1; www.broadinstitute.org) on our dataset. Figure 3.3 
summarises the pathways most significantly enriched in the ko (A) and wt (B) 
condition; such pathways were selected according to their statistical significance 
(p<0,00001) and their involvement in mechanisms of cortical development.  
 
 
Figure 3.3. GSEA analyses performed using canonical pathways as gene sets gave the following outputs: 
(A) the canonical pathways enriched in the ko condition are mainly related to the cell cycle in general (in red) or 
to cell cycle phases (in blue); while, the pathways enriched in the wt condition (B) are related to three main 
categories: ionic channels (in red), intracellular effectors (in blue) and glutamatergic receptors (in green). 
 
Interestingly, the pathways enriched in the ko samples are related to cell cycle and 
the progression through its phases, while those enriched in the wt condition can be 
divided in three different groups according to their involvement with glutamatergic 
receptors transmission (in green), ionic channels transmission (in red) and 
intracellular effectors (in blue). All these processes are obviously crucial for defining 
neuronal functionality. These findings are in agreement with the maturation defect 
previously hypothesized: ko cells, compared to wt, seem to be hold in a progenitorial 
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condition (VZ/SVZ features) and express reduced levels of genes that are 
characteristic of maturing/mature neurons (CP features). 
To validate the obtained data and assess whether the maturation defect begins from 
the earliest processes of neurogenesis, we made use of in vitro cultured Neural 
Progenitor Cells (NPCs) generated from E15.5 cortices. Studying progenitors is of 
particular interest when evaluating neurogenesis, as the fate of a newly born neuron 
depends on both its genetic program and its ability to receive external stimuli since 
its progenitor stage. Accordingly, the neuronal fate strictly depends on the proper 
progression through the cell cycle (Arai and Pierani, 2014).  
At first, we confirmed the in vivo data (Fig. 3.1d), demonstrating that wt NPCs 
express the mRNA of Mecp2 and produce the protein (Fig. 3.4A, b). Subsequently, 
given that NPCs, maintained in proliferating conditions, spontaneously form 
neurospheres, we analysed the number of neurospheres generated starting from 
single cells in a short time lapse as a first evaluation of cell cycle progression. We 
obtained NPCs from wt and ko animals and discovered a slight but statistically 
significant reduction in the number of spheres produced in the ko condition 
compared to wt controls (Fig. 3.4C). Further, we measured the bromodeoxyuridine 
(BrdU) uptake of NPCs cultivated in adhesion, derived from Mecp2 heterozygote 
neurospheres (figure 3.4D); in which wt and ko cells grow in a roughly 50% 
proportion, in order to constrain as much as possible any variability generated from 
differences in cell culture density. BrdU (10 µM) was administered to NPCs every 2 
hours and a fraction of cells was collected 30 min after each administration. A total 
time frame of 14.5 hours, shorter than an entire cell cycle, was selected in order to 
avoid that the same cell could incorporate BrdU twice. The cumulative BrdU 
incorporation analysis highlighted a reduction in the proportion of ko cells uptaking 
BrdU (Fig. 3.4D) and, moreover, the ko reached saturation later than the wt (6,5h wt 
vs 8,5 ko; Fig. 3.4d’). Thus, in agreement with our first data and with previous 
publications the lack of Mecp2 reduces the proliferation rate of cycling cells (Babbio 
et al., 2012; Bergo et al., 2015). 
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Figure 3.4. Mecp2 is expressed in NPCs and its absence alters the entrance in S phase. Confirming in vivo 
data, wt NPCs in vitro express the mRNA of Mecp2 (A) and produce the protein (b, b’). The lack of Mecp2 from 
NPCs causes the reduction of the percentage of neurospheres formed after 3 days of culture in cycling conditions 
(C). Moreover, ko NPCs incorporate less BrdU compared to wt samples, indicating that the lack of Mecp2 alters 
the initiation, or the progression, in S phase (D: cumulative analysis of BrdU incorporation; d’: BrdU 
incorporation). Scale bar: 20 µm in b. 10 µm in b’. Values represent the mean ± the SEM (n=3 wt and ko for the 
neurosphere generation assay; n=3 heterozygous animals for the BrdU incorporation). Statistical analysis: 
Student’s t test *= p<0.05; **=p<0.01; #= almost 0.05. Kolmogorov–Smirnov testing revealed a p <0.001 for the 
cumulative analysis in D. 
 
We proceeded addressing which phase of the cell cycle affects the progression of ko 
progenitors. We started administrating BrdU to cycling NPCs in vitro (again from 
heterozygous embryos) and collecting the cells after 30 minutes; this experiment, 
lasting only half an hour was specifically designed to study, at a roughly steady state, 
the percentage of cells entering the S phase. In line with the data described in figure 
3.4D, we highlighted a reduction in the proportion of ko cells entering in the S phase 
(Fig. 3.5A, B). To count the percentage of cells in the G2 phase we exploited the 
well-recognized dotted staining of phospho-histone H3 (pH3) (Van Hooser., 1998), 
counting the number of dotted pH3 stained nuclei that incorporated BrdU one or two 
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hours before collection (Fig. 3.5C). At both these time points we did not obtain any 
effect driven by the lack of Mecp2 (Fig. 3.5D). Next, we measured the M phase 
length through a time lapse imaging approach. Considering that a complete M phase 
lasts from when cells appear rounded in shape to the loss of any contact between the 
two daughter cells (Fig. 3.5E), we did not detect any defect in the duration of M 
phase (Fig. 3.5F).  
 
 
Figure 3.5. Lack of Mecp2 impairs cell cycle progression. Cultures of NPCs generated from heterozygous 
embryos (A) display cells expressing Mecp2 (x, y) and cells not expressing Mecp2 (w, z) that may or may not 
have incorporated BrdU (x, z and y, w). The proportion of ko NPCs that incorporated BrdU for 30 minutes (thus 
in S phase) is reduced (B), while no changes (C, D) were detected in the proportion of BrdU+ wt and ko cells that, 
displaying a dotted pH3 staining, are considered in G2 (x, y). The length of the M phase (measured through time 
lapse imaging; E) is not impaired (F). Using Fucci probes, it was possible to demonstrate that there is an 
accumulation of cells in the G1 phase, that corresponds to a reduction of cells passing from the G1 to the S phase 
(H). Green cells are in the S/G2/M phases, red cells are in the G1 phase while yellow cells are proceeding from 
the G1 to the S (G). Scale bar: 10 µm for all the images. Values represent the mean ± the SEM (n=3 heterozygous 
animals for the BrdU incorporation, roughly 500 cells per time point, per animal were counted; n=3 ko and wt for 
the time lapse, roughly 400 cells per animal were analysed; n=3 ko and wt, roughly 500 cells per animal were 
counted for Fucci). Statistical analysis: Student’s t test *= p<0.05; #= almost 0.05. 
 
To summarize, the observed lack of defects in the G2 and M phases (Fig. 3.5D, F) 
together with the delay in the S phase entrance (Fig. 3.5B) suggest that Mecp2 null 
NPCs defects in cell cycle progression might be due to a prolonged G1 phase. We, 
thus, proceeded evaluating the length of the G1 phase through the use of Fucci 
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probes (Fluorescent Ubiquitination-based Cell-Cycle Indicator) that are specifically 
designed to be expressed in different cell cycle moments (Sakaue-Sawano et al., 
2008). Cells expressing these probes result red in colour when in G1, green during 
the S/G2/M phases and yellow when progressing from the G1 to the S phase (Fig. 
3.5g). This approach permits to analyse all the cell cycle phases simultaneously on 
the same cells. In line with the results previously described, we did not detect any 
difference in the proportion of cells in S/G2/M phases (green); we found an increase 
in the number of cells in the G1 phase (red), and, importantly, a reduction of the 
percentage of yellow ko NPCs (G1 to S progression) compared to wt (Fig. 3.5H). To 
be noticed and in accordance with the absence of any gross morphological defect in 
ko cortices and the roughly correct layering of the cerebral cortex of both RTT 
animal models and patients, the impairments highlighted so far are not massive 
(Kishi and Macklis, 2004). Recently, we published a study demonstrating, in vitro, a 
reduction of cells in G1 and the increment of cells in G2/M; however such effect was 
highlighted using a different cell type (MRC-5; fetal lung fibroblast). Further, lack of 
Mecp2 in MRC-5 causes a strong affection of cell cycle (less than 50x104 cells after 
30h of cultures compared to more that 200x104 for the wt; (Bergo et al., 2015). This 
result is by no means comparable to the slight reduction of neurosphere formation. 
Our in vitro approach was designed to simplify the analysis of cell cycle progression. 
However, we are well aware that the behaviour of NPCs cultivated in vitro can’t be 
compared to the complexity of in vivo conditions; indeed, in vitro NPCs 
continuously cycle without differentiating in neurons and do not receive external 
cues from post-mitotic neurons. 
To obtain in vivo data, we stained E15.5 cortices for CyclinD1, the principal marker 
of the G1 phase. As expected, we highlighted an increase in the proportion of 
CyclinD1 positive cells in Mecp2 null cortices with respect to wt (Fig. 3.6A). To 
further characterize this increment, we classified the CyclinD1 positive cells in three 
different groups according to the signal intensity: high or low (defining either full G1 
phase (high) or entering/leaving it (low)) and intermediate (defining cells in between 
these two sub-phases; Fig. 3.6b, c). Interestingly, the increased CyclinD1 levels are 
ascribable to an increment in the proportion of weakly positive cells, thus either just 
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entered in the G1 phase or ready to leave it, in agreement with the reduction in cells 
passing through G1 to S highlighted by the Fucci approach (Fig. 3.5H). 
 
 
Figure 3.6. E15.5 cortices display an increment of the G1 marker CyclinD1. The percentage of CyclinD1 
positive cells is increased in ko cortices (A). CyclinD1 expression displays three different levels of intensity as in 
b, where a typical staining in wt tissues is represented. The intensity of the staining corresponds to the three 
different pseudo colours depicted in c: low (blue cells), intermediate (green), high (pink). The increment in the 
percentage of CyclinD1 cells is mainly due to cells expressing it at a low intensity (D). Cells in a fixed grid were 
counted (an average of 500 cells per animal). Scale bar: 30 µm. Values are expressed as percentage versus wt ± 
the SEM (n=9 wt and 6 ko). Statistical analysis: Student’s t test *= p<0.05; **=p<0.01. 
 
Neurogenesis in the cerebral cortex is characterized by the expression of several 
markers expressed in a tightly regulated timing (Hevner et al., 2006). Even within the 
progenitor stage it is possible to find specific features differently marking two main 
classes of cortical progenitors: apical and basal recognizable according to the 
expression of Pax6 and Tbr2 respectively. Given the defects highlighted by the 
bioinformatics approach and our in vitro and in vivo evidences, we focused on the 
establishment of the identity of both these two classes of cortical progenitors. 
Interestingly, the E15.5 Mecp2 null cortices display a slight, but statistically 
significant, increase in the number of Pax6 positive cells and a stronger, in 
magnitude, increase in the number of Tbr2 positive cells (Fig. 3.7B). Interestingly, 
the increment of these two markers accompanies the increase in the number of 
double positive cells (Fig. 3.7B). This evidence is even more important considering 
that by BrdU injection (24 hours before tissues collection) we detected a strong 
increase in the number of triple positive cells (Pax6/Tbr2/BrdU) in ko samples 
compared to wt (Fig. 3.7D). Given that BrdU enables to roughly synchronize the 
cells that are in the S phase at the time of the injection, these data suggest that ko 
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basal progenitors (Tbr2 positive) retain part of the identity of apical progenitors 
(Pax6 positive), a phenotype that physiologically should characterize only a reduced 
number of transitioning cells. 
 
 
Figure 3.7. Lack of Mecp2 alters the expression of different progenitorial markers. A: E15.5 ko cortices 
display an increased number of Pax6 (marker of apical progenitors; a’’) cells, Tbr2 (marker of basal progenitors; 
a’) cells and double positive cells (cells transitioning between the two conditions) (B). C: the increment is 
confirmed also when cells are synchronized using BrdU injection (24 hours before the tissue collection; D). The 
images displayed in A and C represent the expression of the different markers in wt animals. Roughly 500 cells 
(counted in a binned grid) were counted per animal according to Pax6 or Tbr2 immunoreactivity. Scale bar: 50 
µm. Values are expressed as percentage versus wt ± the SEM (n=9 wt and 6 ko). Statistical analysis: Student’s t 
test *= p<0.05; **=p<0.01. 
 
A defect in the transition between the stage of progenitor to the post-mitotic one 
could thus be hypothesized. We proceeded testing the switch between these two cell 
populations by administering BrdU to pregnant mice and collecting embryos after 24 
hours (E14.5 on E15.5), a time window sufficient for a complete cell cycle, enabling 
the cell to either re-enter in the cycle or differentiate. By using a marker of cycling 
cells such as Ki67, we detected in the Mecp2 null cortices a slight increase in the 
number of Ki67/BrdU cells (Fig. 3.8B). As we did not expect cells to re-enter the cell 
cycle faster in the ko animals compared to wt, we hypothesized that the observed 
alteration could be caused by a slower transition of Mecp2 defective cells from the 
proliferative to the post-mitotic state, therefore leading to a less sharply defined cell 
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identity. To confirm this hypothesis, we stained E15.5 cortices with Ki67 (a marker 
that does not distinguish between apical and basal progenitors) and an early marker 
of post-mitotic cells (Neun). As expected, we obtained a statistically significant 
increase in the number of Ki67/Neun double positive cells, confirming that cells that 
should be post-mitotic retain a proliferative identity for a longer period (Fig. 3.8D).  
 
 
Figure 3.8. Lack of Mecp2 alters the number of cells transitioning from one developmental stage to the 
next one. A: the percentage of cells expressing the cell cycle marker Ki67 (a’) (synchronized with the BrdU 
injection; a’’) is increased in ko samples (B). C: the increment of the Ki67/BrdU positive cells is possibly 
explained by the increment of cells transitioning from the mitotic to the post-mitotic condition (Ki67/Neun 
double positive cells (c’, c’’), Neun defines post-mitotic neurons; D). E: accordingly, the switch between basal 
progenitors to neurons is altered (e), as the number of the double positive cells is increased (F). The images 
displayed in a, c and e represent the expression of the different markers in wt animals. Roughly 500 cells 
(counted in a binned grid) were counted per animal according to Ki67, BrdU or Neun immunoreactivity. Scale 
bar: 25 µm. Values are expressed as percentage versus wt ± the SEM (n=9 wt and 6 ko). Statistical analysis: 
Student’s t test *= p<0.05; **=p<0.01. 
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To reinforce these observations, we analysed the progression leading from basal 
progenitors to Neun positive post-mitotic cells. We did not analyse the transition of 
apical (Pax6 positive) progenitors given these produce an overall low number of 
post-mitotic cells (through direct neurogenesis; (Attardo et al., 2008). Stunningly, the 
number of Tbr2 and Neun double positive cells resulted increased in ko samples 
compared to wt (Fig. 3.8F). Moreover, even the number of Pax6/Tbr2/BrdU triple 
positive cells (BrdU was administered, again, 24 hours before tissue collection) 
resulted increased, further confirming in ko cortices the increased size of the 
population of cells presenting an identity that is yet not completely defined (Fig. 
3.8F). 
Taken together, these in vivo data lead us to the hypothesis that a delay in the switch 
from one identity to the next one affects Mecp2 null neuronal progenitors 
independently whether they are switching from one type of progenitors to the other 
(Fig. 3.7) or from progenitors to immature neurons (Fig. 3.8).  
 
 
Figure 3.9. The number of Mecp2 ko ND1+ cells is increased compared to wt. ko samples display a rather 
large population of ND1+ cells ectopically located within the VZ; accordingly, the number of such cells resulted 
increased in the SVZ and IZ (A, B). In C the overall increment of ND1+ cells is represented. Scale bar: 50µm 
Values are expressed as percentage versus wt ± the SEM (n=6 wt and 6 ko). Roughly 500 cells (counted in a 
binned grid) were counted per animal according to ND1 staining. Statistical analysis: Student’s t test *= p<0.05; 
**=p<0.01.  
 
However, our evidences were produced exploiting markers that differentiate mitotic 
and post-mitotic populations; the NeuroD1 marker would define a transient stage that 
lasts from the latest phases of cell cycle to the earliest post-mitotic life of a newly 
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born neuron. We thus counted NeuroD1 positive cells in both wt and ko cortices at 
E15.5. In line with our hypothesis, we found an increment of NeuroD1 positive 
transitioning cells (Fig. 3.9A, B) that is even more evident when counted within the 
pool of BrdU (24 hours) positive cells. 
Importantly, we believe that our results suggest that in the absence of Mecp2, in the 
neuronal lineage, cells express ectopic markers because they need more time to 
define their next phenotype; this impairment will lead to a delayed expression of 
genes characterizing more mature neurons, as demonstrated by our microarray 
analysis (Fig. 3.2C-E). We thus focused on characterizing the possible consequences 
of this defect beginning from the three main classes of genes that resulted 
deregulated in null samples from the analysis of the microarray data: glutamatergic 
receptors, ionic channels and intracellular signalling (Fig. 3.3B). The transcription of 
many ionotropic (AMPA and NMDA) and metabotropic glutamatergic receptors 
subunits was analysed through quantitative PCR (Fig. 3.10A) at different time points. 
We found that AMPA receptors subunits transcripts were mostly down-regulated 
starting from E15.5 through E18.5; such effect persisted even at post-natal levels 
(P8). NMDA subunits levels were mostly normal at E15.5 and, depending on the 
subunit analysed, start to be deregulated later on. Lastly, some subunits of the 
metabotropic receptors resulted down-regulated only at P8. This gradient of 
expression is most likely ascribable to the different timing in the activation of the 
transcription of these receptors in the developing cortex, accordingly, we were not 
able to detect any transcription of metabotropic receptors at E15.5.  
Next, we analysed the expression of different ion channels subunits (Ca2+, Cl-, K+ 
and Na+), which begins at E15.5 and persists later on (Fig. 3.10B). The deregulation 
of these membrane molecules is accompanied by the down-regulation of intracellular 
effectors, such as Gnaq, Adcy9, Camk2β, Camk2d and Plcg2 (all molecules involved 
in intracellular signalling). Remarkably all these transcripts resulted mostly down-
regulated at E15.5 and E18.5, and, for the most part, their expression was not 
renormalized by P8 (Fig. 3.10C). 
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Figure 3.10. The expression of genes characterizing maturing/mature neurons is altered in the Mecp2 ko. 
The qPCR analysis of cortices lacking Mecp2 displays the transcriptional deregulation of subunits composing 
glutamatergic receptors (A) and ion channels (B) and different components of intracellular signalling (C). Values 
are expressed as percentage versus wt ± the SEM (n =4 wt vs. ko in A and B; n =8 wt vs. 8 ko in C). Statistical 
analysis: Student’s t test *= p<0.05; **=p<0.01 (Bedogni et al., 2015). 
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Interestingly, the expression of this group of genes characterizes maturing/mature 
electrically active neurons integrating (or integrated) in functional networks and 
reacting to external stimuli with proper intracellular responses. Given the mentioned 
deregulation of many genes involved in cortical excitability, we investigated whether 
neurons from ko animals show any impairment in their response to external stimuli.  
Thus, we produced neuronal cultures from E15.5 cortices of wt and ko animals and 
evaluated cellular responsiveness to chemical (glutamate) and electrical stimulation 
in terms of calcium transients. At first, we characterized the responses of neurons to 
glutamate in wt conditions at very early stages of development (DIV3) by 
stimulating neurons with 25 µM glutamate. To block any effect triggered by stimuli 
other than glutamate, we added to the cultures the following blockers: Tetradotoxin 
(TTX to block Na+ currents), Nifedipine (to block voltage gated Ca2+ channels) and 
Bicucullin (to block GABAergic receptors) respectively. In such conditions 
glutamate drove the strong Ca2+ wave depicted in figure 3.11a. To dissect whether 
such effect was mostly driven by AMPA or NMDA receptors, we first blocked 
AMPA receptors with CNQX (Fig. 3.11a’). Interestingly, AMPA receptors mediated 
responses after glutamate stimulation resulted by far the most predominant, as 
depicted in the graph in figure 3.11a’’’. The fact that at this stage of maturation 
AMPA and NMDA are the only receptors mediating glutamate responses is 
demonstrated by the lack of responses driven by the addition of both CNQX and 
APV (NMDA blocker) to the medium (Fig. 3.11a’’). To test responsiveness after 
field electrical stimulation (2 seconds at 30 Hz), we added CNQX, APV and 
Bicucullin to exclusively evaluate evoked calcium transients mediated by ionic 
channels (Fig. 3.11b). In such conditions we mostly abolished such responses by 
adding Nifedipine to the medium (roughly 75%; Fig. 3.11 b’), while no Ca2+ waves 
could be recorded after the administration of TTX alone (Fig. 3.11b’’). These 
demonstrates that the calcium transients are mainly mediated by L-type Ca2+ 
channels (Fig. 3.11b’’’) and that their activation is mediated by the activation of Na+ 
channels. 
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Figure 3.11. Mecp2 ko neurons exhibit lower calcium responses upon both glutamate and electrical 
stimulation. Glutamate stimulation (25 µM) of neurons generated a strong calcium response (a) that is strongly 
reduced by adding 20 µM CNQX (a’) and completely abolished by adding 20 µM CNQX and 50 µM APV (a’’), 
indicating that these responses are for the most part ascribable to AMPA receptors (a’’’). Electrical field 
stimulation (2s at 30 Hz) generates a calcium response (b) that is strongly reduced by 20 µM Nifedipine (b’) and 
completely abolished by 1 µM TTX (b’’), indicating that such response is mainly due to the activation of L-type 
Ca2+ channels, mediated by the activation of Na+ channels (b’’’). The analyses of calcium changes upon either 
glutamate (C–F) or electrical stimulation (G–J) were performed on wild type and Mecp2 ko neurons at different 
DIV (F, J) and resulted reduced at all the examined DIV fro the glutamate and at DIV3 for the electrical 
stimulation (E, I: cumulative analysis of DIV3 neurons). F, J: data represent the mean value of the ratio between 
ΔF and F0 at different time points. Values are expressed as the mean ± the SEM (n=4 wt and 3 ko). Statistical 
analysis: Student’s t test *= p<0.05 (Bedogni et al., 2015). 
 
In such conditions, we next studied the responses generated by either glutamate or 
electrical stimulation of DIV3, 7 and 12 wt and ko neurons. As depicted in figure 
3.11C-F, glutamate (25 µM in presence of Nifedipine, TTX and Bicucullin) evoked 
responses were reduced in Mecp2 null neurons at all the analyzed time points, 
therefore indicating a persistence of the impaired responsiveness. Interestingly, even 
when stimulated with field electric potentials (2 seconds at 30 Hz), ko neurons 
responses were reduced with respect to wt; however, such reduction was detected at 
DIV3 but not at later time points. We suggest that all in all these evidences indicate 
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that Mecp2 null cortices are delayed in their ability to produce responses when 
stimulated probably because of their incomplete transition towards a more mature 
identity. 
Whether this could affect not only the functionality by which Mecp2 null neurons 
respond to stimuli but their actual structural maturation is hard to predict, however, 
the morphological analysis of ko neurons cultivated in vitro for only 3 days produced 
stunning evidences. In fact, we found that already at this early stage of development 
the nuclear size of ko neurons is reduced (Fig. 3.12A) and their long neurites (longer 
than 100 µm; Tuj1+) are shorter (Fig. 3.12B; no effects were detected on neurites 
shorter than 100 µm; Fig. 3.12C). This result is of extreme interest as it suggests that 
maturation defects driven by the lack of Mecp2 affect neuronal morphology ever 
since early development. 
 
 
Figure 3.12. Morphological defects of DIV3 neurons lacking Mecp2. Already at such an early time points 
(DIV3) the nuclear size of ko neurons resulted reduced compared to wt (A). Moreover, the long neurites (longer 
that 100 µm) are shorter in ko neurons (B), while no effect is detectable in short neurites (shorter than 100 µm; 
C). Statistical analysis: Student’s t test *= p<0.05; **=p<0.01. Kolmogorov–Smirnov testing revealed a p <0.001 
for the cumulative analysis in A and <0.05 for the one in B, while resulted not significant for the one in C. n=3 ko 
and 4 wt (Bedogni et al., 2015). 
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4. DISCUSSION 
 
Ever since the discovery of the link between MeCP2 mutations and RTT (Amir et al., 
1999), many efforts in the field focused on identifying the physiological functions of 
the protein, in order to possibly restore them and ameliorate the conditions of the 
affected girls. One of the main characteristics of classical RTT is that females appear 
normal at birth, while overt symptoms arise during the first infancy (around 6-18 
months of life) in a developmental phase that coincides with the peak of 
synaptogenesis in babies (Smeets et al., 2012). This evidence, together with the 
demonstration of the central role of the brain in RTT pathogenesis (Chen et al., 2001; 
Guy et al., 2001), suggested that RTT is a neurodevelopmental disorder, mainly 
affecting post-natal development. Indeed, it was demonstrated that Mecp2 has a role 
in proper neuronal arborisation (Armstrong, 2005) and in controlling synaptic 
activity, through the regulation of the initial formation of synaptic contacts (Chao et 
al., 2007). Nevertheless, earlier developmental phases might be impaired in RTT, as 
a growing number of evidences demonstrated that RTT patients and mice manifest 
subtle, but consistent, signs of the pathology also during the so called “pre-
symptomatic” phase immediately after birth (Nomura, 2005; Picker et al., 2006), 
leading us to hypothesize that Mecp2 may have a role during embryonic 
development. 
In the past, as previously mentioned, only few studies addressed the possible role of 
Mecp2 in embryos, but these did not lead to conclusive evidences (Kishi and 
Macklis, 2004; Schmid et al., 2008; Shahbazian et al., 2002). To shed light on this 
issue, we investigated the role of Mecp2 during early cerebral cortex development. 
The choice of studying cerebral cortex resided in the fact that this area is particularly 
involved in RTT pathogenesis; RTT patients, in fact, display cortical morphological 
abnormalities and strong cognitive impairments, often accompanied by seizures, 
which are mainly due to cortical dysfunctions (Armstrong, 2005). 
The embryonic cerebral cortex is composed by heterogeneous cell populations that 
can be easily distinguished according to their maturation stage that is strictly linked 
to their positioning within the cortical wall and to the expression of specific 
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transcription factors. The 6-layered mature cortex arises from processes that are 
temporally and spatially defined ever since the establishment of Neuroepithelial 
Cells (NECs), composing the primordial dorsal telencephalon; such cells give raise 
to all the glutamatergic neurons composing the adult cortex (Fig. 4.1A). With the 
onset of neurogenesis (roughly at E11), NECs switch their mode of mitotic division 
from symmetric/proliferative to asymmetric/neurogenic, thus becoming Radial Glial 
Cells (RGCs; or Apical Progenitors, AP). 
RGCs are not located within the entire cortical wall, as while neurogenesis proceeds 
and the embryonic cortex thickens, they remain in an apical area (i.e. close to the 
ventricle) that is defined as Ventricular Zone (VZ). The asymmetric division of these 
progenitors give rise to one RGC and either directly to a neuron or to a second type 
of progenitor, known as Intermediate Progenitor Cell (IPCs; or Basal Progenitor 
(BP), i.e. closer to the pia). IPCs are multipolar progenitors that symmetrically divide 
in the Sub-Ventricular Zone (SVZ) of the cortex. These cells can enter the cell cycle 
once, giving rise to two neurons, or twice, originating first two new IPCs that then 
generate neurons, thus exponentially expanding the neuronal pool (Farkas and 
Huttner, 2008; MuhChyi et al., 2013).  
 
 
Figure 4.1. The development of the cerebral cortex. The cerebral cortex arises from the dorsal telencephalon 
that at E10 is formed by NECs symmetrically cycling to expand the progenitorial pool. Subsequently, NECs 
switch their division mode to asymmetric/neurogenic, becoming RGCs. Neurons are produced directly by RGCs 
or by IPCs that, dividing symmetrically, exponentially expand the neuronal production (A). Each cellular type 
populating the cortex is easily recognizable thanks to the expression of specific markers (B): Pax6 by RGCs, 
Tbr2 by IPCs, late mitotic/early post-mitotic cells by ND1, neurons by Neun (modified from MuhChyi et al. 
2013; Hevner et al. 2006). 
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Interestingly, all the populations described are easily distinguishable in the cortical 
wall thanks to the expression of specific markers: RGCs express Pax6 and IPCs 
Tbr2. The progression through the next phases of neurogenesis requires the 
temporally regulated expression of NeuroD1, identifying cells switching from a 
progenitorial stage to a post-mitotic one, and Neun identifying early and late born 
neurons (Fig. 4.1B) (Hevner et al., 2006). 
Given that all these are transcription factors, it is quite evident that a finely tuned 
transcriptional mechanism regulates the progression through the different phases 
enabling the production of post-mitotic neurons. The first wave of post-mitotic 
neurons migrates radially towards the pial surface forming the Pre-Plate (PP); the PP 
is then split into two layers (the Marginal Zone and the Subplate; MZ and SP) by a 
second wave of post-mitotic neurons that settle in between the PP giving rise to the 
Cortical Plate (CP, surrounded apically by the SP and basally by the MZ).  
 
 
Figure 4.2. The 6-layered cerebral cortex is formed following an inside-out fashion. Neurogenesis begins in 
mice roughly at E11 and comprises different waves of production of post-mitotic neurons. These waves of 
neurons are produced in a specific temporal sequence and migrate towards the pia forming the 6-layered cortex 
following an inside-out dynamic: the oldest neurons form the inner layer and the youngest form the most 
superficial ones (Gupta et al., 2002). 
 
All the subsequent waves of newly born neurons will migrate radially through the 
Intermediate Zone (IZ) in an inside-out fashion (Fig. 4.2): the oldest neurons form 
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the inner layers (L6-5-4-3 respectively) and the youngest cells more superficial ones 
(L2). The most superficial layer (L1) is the remnant of the MZ, in which CR cells 
reside. Immediately before birth, RGCs switch from the production of neurons/IPCs 
to the production of glial cells that continues post-natally (Gupta et al., 2002; 
Paridaen and Huttner, 2014). 
We analysed the developing cortex at E15.5, as it represents the peak of 
corticogenesis. Moreover, at this stage only few GABAergic neurons have already 
migrated within the cortex and glial production is yet not started, thus the 
heterogeneity of the cellular population composing the E15.5 cortex is limited to 
progenitors and post-mitotic glutamatergic neurons. In this context, we demonstrated 
that all the cell types populating the cortex (progenitors, early and late post-mitotic 
neurons) express Mecp2, possibly suggesting that the protein exerts a function during 
the entire life of a neuron. Given the well-accepted role of Mecp2 in regulating 
transcription, we hypothesized that its absence could generate transcriptional 
derangements. Indeed, the transcriptional profile of E15.5 ko cortices display subtle, 
but consistent, alterations affecting many genes, rather than a few genes strongly 
deregulated. These results might reflect the hypothesized global function of Mecp2 
(Skene et al., 2010). To extract meaningful information from this kind of dataset, it 
was thus necessary to analyse the enrichment of sets of genes (composed by 
transcripts sharing functional similarities or expressed by a common cellular type) 
rather than focusing on single, strongly deregulated, genes. Such approach enables to 
highlight the extent by which a “sum” of small transcriptional defects could be 
suggestive of the deregulation of an entire molecular mechanism (Bedogni et al., 
2014; Subramanian et al., 2005). Through GSEA, that enables this kind of analysis, 
we obtained the enrichment of the proliferative (progenitorial) identity in the ko 
sample and the enrichment of the post-mitotic (neuronal) identity in the wt samples, 
suggesting that neuronal maturation in the ko cortex may be delayed. This result 
represents a first hint that already at early embryonic stages Mecp2 deficiency can 
produce slight but significant derangements in the mechanisms regulating the timing 
of the transition from cell cycle to post-mitotic differentiation. 
Neurogenesis is based on a strict cross talk between cell division and differentiation; 
since these two processes are closely coordinated, defects in either one mechanism 
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could deeply alter the establishment of a functional network. Given the 
aforementioned delay by which the post-mitotic identity is acquired, it is very likely 
that the early mitotic steps required for the establishment of cortical network is 
impaired in the Mecp2 null embryonic cortex. We thus searched for any possible 
alteration of the rate of cell cycle progression and the balance between cell cycle re-
entry and exit in Mecp2 null samples (Dehay and Kennedy, 2007). 
We demonstrated that the cell cycle progression is slightly delayed in ko NPCs due 
to impairments affecting the time window covered by the G1 phase, both in vitro and 
in vivo. This is of particular interest, as the G1 phase is crucial in determining 
whether a progenitor will re-enter the cell cycle or rather differentiate. Indeed, a 
precise step in G1, known as “restriction point”, defines when the cell is definitively 
committed to re-enter the cell cycle; after this point, a transcriptional mechanism 
enabling the transition from G1 to S phase is activated reinforcing, through a positive 
feedback, the cell cycle progression that then proceeds independently from external 
cues (Bertoli et al., 2013). It is well known that the length of G1 increases during late 
steps of neurogenesis compared to early ones (Arai et al., 2011) possibly enabling 
the progenitors to respond to external stimuli and to accumulate different factors 
leading to either cell cycle exit or re-entry (Hardwick et al., 2014). The alterations 
encountered by Mecp2 null cells in G1 phase may be thus suggestive of a 
problematic switch from proliferation to differentiation.  
In light of this, we next verified whether the previously demonstrated delayed 
progression through the cell cycle alters neuronal maturation in vivo. Interestingly, 
our data show, in the null samples, a statistically significant increase of the cells co-
expressing markers that normally are progressively switched on and off by a cell 
during its transition from RGC to IPC (Pax6+ à Tbr2+; Fig. 4.3). This does not imply 
that the Mecp2 null cortex displays an increased total number of either RGCs or IPCs 
but, rather, that the fate of such cells is not as sharply defined as in wt samples, with 
IPCs retaining some RGCs identity. Accordingly, we found an increased number of 
KI67/Neun and Tbr2/Neun double positive cells, demonstrating that part of the 
progenitorial identity is still featured by post-mitotic neurons; of note, these results 
well match with the increased representation of proliferative identity highlighted 
through GSEA. The increased number of cells expressing markers characterizing two 
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different populations could imply that Mecp2 deficiency causes a defect in defining 
the identity of a cell. As mentioned, during the development of the cerebral cortex 
the sequential expression of transcription factors generates a “combinatorial code” 
that is fundamental to specify the final cellular fate (Englund et al., 2005; Hevner et 
al., 2006). Thus, the altered G1 phase may cause the persistence of a slightly 
unrefined identity that may delay the progression towards a fully matured stage, 
rather than affecting neurogenesis in terms of number of neurons produced. This is in 
agreement with the fact that both in humans and animal models the gross 
morphology of the MECP2 defective cerebral cortex and the average number of 
neurons composing it are not impaired (Armstrong, 2005; Kishi and Macklis, 2004).  
 
 
Figure 4.3. Cell maturation in the cerebral cortex is accompanied by the sequential expression of 
transcription factors. These markers are co-expressed in a cell for restricted time lapses, during the switch of 
their identity (modified from Hevner et al. 2006) 
 
Accordingly, a similar phenotype was previously reported by Smrt et al, 
demonstrating that, during adult neurogenesis in the hippocampus, Mecp2 null 
samples display an increased number of transitioning neurons switching from 
immature stages to mature ones, suggesting that cells lacking Mecp2 fail in properly 
differentiating towards established neurons (Smrt et al., 2007). By unmasking an 
increased number of cells expressing ND1, we further confirmed the increment of 
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transitioning cells in null samples. Indeed, ND1 is a marker of late mitotic/early post-
mitotic phases that enables to identify cells switching from proliferation to 
differentiation. 
Overall, the impaired transition between mitotic and post-mitotic identity may be 
linked with the maturation impairments previously suggested by our transcriptional 
analysis highlighting the enrichment of the identity of the post-mitotic compartment 
in the wt samples. Indeed, we demonstrate that Mecp2 null cortices are characterized 
by the down-regulation of different glutamate receptors and ion channel subunits, 
transcripts that are mostly expressed by maturing post-mitotic neurons. Such defects 
are involved in the reduced capability of neurons to respond to external stimuli such 
as glutamate or current injection, as demonstrated by calcium imaging analysis. In 
accordance with our findings, it is known that the establishment of networks is 
impaired when Mecp2 is absent (Dani et al., 2005) and there is a strict link between 
externally driven responses and neuronal arborisation (Spitzer, 2006). Importantly 
and new for the field, we demonstrated that in the earliest phases of maturation, 
Mecp2 null neurons display morphological alterations that are typically displayed by 
null neurons in adulthood (reduced nuclear size and shorter neuritis). A link between 
such early morphological and functional phenotype and the deranged transition 
between proliferative and post-mitotic phases could be easily hypothesized: cells 
encountering problems in defining their identity are possibly delayed in their 
subsequent maturation. Interestingly, this could also directly affect the proliferative 
compartment itself; in fact, it is known that post-mitotic neurons influence the rate of 
proliferation/differentiation of progenitors residing in the VZ and SVZ thanks to 
feedback mechanisms (through descending axons) (Dehay and Kennedy, 2007). 
Given the known problems in synaptogenesis, this mechanism could very likely be 
affected in null samples. 
To conclude, we demonstrate that during cortical development lack of Mecp2 affects 
cell fate decision most likely delaying post-mitotic neuronal maturation; this is 
possibly mediated by transcriptional deregulations delaying the acquirement of a 
more mature identity by turning off the previous one. This delay could drive, beside 
other effects, the reduced expression of membrane molecules necessary to respond to 
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external stimuli, thus reducing cell responses to the environment delaying the 
integration of immature neurons in a fully established network. 
We believe that RTT phenotype is thus the sum of different alterations occurring 
ever since embryonic developmental stages that worsen during early infancy, 
generating the overt establishment of symptoms.  
Our hypothesis of a role for Mecp2 during cell differentiation is indeed reasonable, 
as stem cells, differentiating to more specialized phenotypes, progressively restrict 
their fate by repressing specific genes. This transcriptional regulation is, at least 
partially, ascribable to epigenetic changes that modify the chromatin structure and 
fold chromosomal regions into non-transcriptionally active heterochromatin. Since 
epigenetic mechanisms are involved in this process, it is possible to infer that lack of 
an epigenetic factor such as Mecp2 can generate impairments in the interpretation of 
the “methylation signature” characterizing the transcriptional identity that 
specifically define each cell type (MacDonald and Roskams, 2009; MuhChyi et al., 
2013).  
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a  b  s  t  r  a  c  t
Rett  syndrome  (RTT)  is  a devastating  genetic  disorder  that  worldwide  represents  the  most  common
genetic  cause  of  severe  intellectual  disability  in  females.  Most  cases  are  caused  by  mutations  in  the  X-
linked  MECP2  gene.  Several  recent  studies  have  demonstrated  that  RTT  mimicking  animal  models  do  not
develop  an  irreversible  condition  and  phenotypic  rescue  is  possible.  However,  no  cure  for  RTT has  been
identified  so  far,  and  patients  are  only  given  symptomatic  and  supportive  treatments.  The  development
of  clinical  applications  imposes  a more  comprehensive  knowledge  of  MeCP2  functional  role(s)  and  their
relevance  for  RTT  pathobiology.  Herein,  we  thoroughly  survey  the  knowledge  about  MeCP2  structure  and
functions,  highlighting  the  necessity  of identifying  more  functional  domains  and  the  value  of  molecular
genetics.  Given  that,  in  our  opinion,  RTT  ultimately  is generated  by  perturbations  in gene  transcription
and  so  far no  genes/pathways  have  been  consistently  linked  to  a dysfunctional  MeCP2,  we  have  used
higher-level  bioinformatic  analyses  to  identify  commonly  deregulated  mechanisms  in  MeCP2-defective
samples.  In  this  review  we  present  our  results  and discuss  the possible  value  of  the  utilized  approach.
©  2014  Elsevier  Ltd.  All  rights  reserved.
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Methyl-CpG Binding Protein 2 (MeCP2) Localizes at the
Centrosome and Is Required for Proper Mitotic Spindle
Organization*□S
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Background:MeCP2 is a multifunctional protein whose full spectrum of activities remains enigmatic.
Results: MeCP2 localizes at the centrosome and at the mitotic spindle. Its loss causes deficient spindle morphology and
microtubule nucleation and prolonged mitosis.
Conclusion: Through its centrosomal localization, MeCP2 regulates cell growth and cytoskeleton stability.
Significance: This novel MeCP2 function may improve our comprehension of MeCP2 under physiological and pathological
conditions.
Mutations inMECP2 cause a broad spectrum of neuropsychi-
atric disorders of which Rett syndrome represents the best
defined condition. Both neuronal and non-neuronal functions
of the methyl-binding protein underlie the related pathologies.
Nowadays MeCP2 is recognized as a multifunctional protein
thatmodulates its activity depending on its protein partners and
posttranslational modifications. However, we are still missing a
comprehensive understanding of allMeCP2 functions and their
involvement in the related pathologies. The study of human
mutations often offers the possibility of clarifying the functions
of a protein. Therefore, we decided to characterize a novel
MeCP2 phospho-isoform (Tyr-120) whose relevance was sug-
gestedby aRett syndromepatient carrying aY120Dsubstitution
possibly mimicking a constitutively phosphorylated state.
Unexpectedly, we found MeCP2 and its Tyr-120 phospho-iso-
form enriched at the centrosome both in dividing and postmi-
totic cells. The molecular and functional connection of MeCP2
to the centrosome was further reinforced through cellular and
biochemical approaches.We show that, similar tomany centro-
somal proteins, MeCP2 deficiency causes aberrant spindle
geometry, prolongedmitosis, and defects inmicrotubule nucle-
ation. Collectively, our data indicate a novel function ofMeCP2
that might reconcile previous data regarding the role of MeCP2
in cell growth and cytoskeleton stability and that might be rele-
vant to understand some aspects of MeCP2-related conditions.
Furthermore, they link the Tyr-120 residue and its phosphory-
lation to cell division, prompting future studies on the relevance
of Tyr-120 for cortical development.
Methyl-CpG binding protein 2 (MeCP2) was first described
as an epigenetic factor that binds specifically to methylated
DNA and represses transcription through the recruitment of
chromatin remodeling complexes containing histone deacety-
lase activities (1, 2). Mutations in the X-linked MECP2 gene
were later found in several patients affected by Rett syndrome
(RTT,4OMIMno. 312750), a devastating neuronal disease that,
because of its incidence, is considered to be one of the main
causes of severe intellectual disabilities in girls (3). Since then,
hundreds of different mutations in MECP2 have been associ-
ated with RTT or, less frequently, with other forms of intellec-
tual disability.
AlthoughMECP2mutations have profound effects on brain
functions, several recent studies have demonstrated that RTT is
not an irreversible condition inmice because phenotypic rescue
is possible (4).MeCP2 studies have therefore been boosted dra-
matically, leading to a progressive expansion of MeCP2 func-
tions beyond the original role of the protein in transcriptional
repression through the recruitment of chromatin remodeling
complexes (5). In 2003, Georgel et al. (6) proposed thatMeCP2,
when highly abundant, might work directly (without other
corepressors or enzymatic activities) as a potent chromatin
condensing factor . Accordingly, Skene et al. (7) have demon-
strated that, in mature neurons where MeCP2 levels are suffi-
ciently high to saturate methylated DNA but not in non-neu-
ronal cells characterized by 10–30 times less MeCP2, the
protein can substitute histone H1 and function as a global
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Development Precede the Onset of Overt Neurological
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Abstract
MeCP2 is associated with several neurological disorders; of which, Rett syndrome undoubtedly represents the most frequent. Its
molecular roles, however, are still unclear, and data from animal models often describe adult, symptomatic stages, while MeCP2
functions during embryonic development remain elusive.We describe the pattern and timing ofMecp2 expression in the embryonic
neocortex highlighting its low but consistent expression in virtually all cells and show the unexpected occurrence of transcriptional
defects in theMecp2 null samples at a stage largely preceding the onset of overt symptoms. Through the deregulated expression of
ionic channels and glutamatergic receptors, the lack of Mecp2 during early neuronal maturation leads to the reduction in the
neuronal responsiveness to stimuli. We suggest that such features concur to morphological alterations that begin affectingMecp2
null neurons around the perinatal age and become evident later in adulthood. We indicate MeCP2 as a key modulator of the
transcriptional mechanisms regulating cerebral cortex development. Neurological phenotypes ofMECP2 patients could thus be the
cumulative result of different adverse events that are already present at stages when no obvious signs of the pathology are evident
andareworsenedby later impairmentsaffecting thecentral nervous systemduringmaturationandmaintenanceof its functionality.
Key words: embryonic cerebral cortex development, intrinsic neuronal excitability, MeCP2 null cortex, neurological disorders,
transcriptome
Introduction
Rett syndrome (RTT) is a devastating genetic disorder that world-
wide represents the most common genetic cause of severe intel-
lectual disability in females. Typical RTT patients appear to
develop normally throughout the first 6–18 months of life when
neurological development arrests and a regression phase leads
to the loss of previously acquired skills. During and after the re-
gression phase, patients develop a host of typical symptoms
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